株式会社 シン・コーポレーションBio X Cell(BXC)社は、in-vivo/in-vitro実験用抗体の信頼できるサプライヤーです。アメリカのボストン近郊、ニューハンプシャー州レバノンにあり、1997年から生物医学研究用のモノクローナル抗体を生産しています。BXC社の目的は、高品質の抗体を優れた価格で提供し、優れた顧客サービスでバックアップすることで、科学的発見とイノベーションの推進を促進することです。そのため、in vivo の前臨床研究に必要な大量の、十分に特徴付けられた抗原と新規抗原の両方を標的とする、防腐剤や安定剤を含まない超高純度の低エンドトキシン抗体の製造に取り組んでいます。25年の経験に裏打ちされた、in vivo用モノクローナル抗体の多種のカタログ製品を高品質、低価格で提供します。
BXC社は日本のユーザー様へ直接販売はしておりません。
お見積りは、Bio X Cell社の正規日本代理店の当社へご依頼ください。
価格表
価格表（通常・アカデミック）： 2024年11月18日（PDFファイル）
*年初のメーカー価格改定前に、特別価格で販売いたします！
価格表有効期間： 2024年11月18日～2024年12月25日
*価格表の閲覧にパスワードが必要となりますので、お問合せください。
*ご注文（配送）ごとに取扱手数料2.5万円（送料･通関手数料等含む・税別）を申し受けます。
アカデミックプライス適用申込書
アカデミックプライス適用申込書フォーム： 大学等、非営利組織に所属のユーザーはアカデミックプライスが適用されますので、注文時にこちらの申込書をご提出ください。（Wordファイル）
新製品
| 品番 | 品名 | クローン | Isotype |
| BE0038 | InVivoMAb anti-mouse CD11c | N418 | IgG2 |
| BE0431 | InVivoMAb anti-Zika virus E protein DIII-LR | ZV-67 | IgG2c, κ |
| BE0432 | InVivoMAb anti-Dengue virus type 2 E protein DIII | DV2-96 | IgG2c, κ |
| BE0433 | InVivoMAb anti-Eastern equine encephalitis virus E2 protein | EEEV-3 | IgG2c, κ |
| BE0434 | InVivoMAb anti-Powassan virus E protein | POWV-63 | IgG2c, κ |
| BE0435 | InVivoMAb anti-Venezuelan equine encephalitis virus E2 protein | VEEV-57 | IgG2c, κ |
| BE0436 | InVivoMAb anti-human VISTA | GG8 | IgG1, κ |
| BE0437 | InVivoMAb anti-Dengue virus type 4 E protein DIII | DV4-E88 | IgG2c, κ |
| BE0438 | InVivoMAb anti-SARS-CoV-2 S protein (RBD) | SARS2-38 | IgG1, κ |
| BE0439 | InVivoMAb anti-rat CD4 | W3/25 | IgG1, κ |
| BE0440 | InVivoMAb anti-mouse CXCL10 (IP-10) | 1F11 | IgG |
| BE0441 | InVivoMAb anti-human IL-10 | JES3-19F1 | IgG2a, κ |
| CP179 | RecombiMAb HIS human IgG1 F(ab) isotype control, anti-hen egg lysozyme | N/A-CP179 | IgG1, κ |
| CP180 | RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme | N/A-CP180 | IgG2, κ |
| CP181 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | N/A-CP181 | IgG4, κ |
| CP183 | RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme | N/A-CP183 | IgG4, κ |
| SIM0033 | InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar) | Tiragolumab | IgG1, κ |
| SIM0034 | InVivoSIM anti-human CD38 (Daratumumab Biosimilar) | Daratumumab | IgG1, κ |
| SIM0035 | InVivoSIM anti-human CD25 (IL-2Rα) (Daclizumab Biosimilar) | Daclizumab | IgG1, κ |
| SIM0036 | InVivoSIM anti-human TSLP (Tezepelumab Biosimilar) | Tezepelumab | IgG2, λ |
| SIM0037 | InVivoSIM anti-human PD-1 (Cemiplimab Biosimilar) | Cemiplimab | IgG4, κ |
| SIM0038 | InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) | Tislelizumab | IgG4, κ |
*2024年7月5日追加
製品カテゴリー
*Bio X Cell社サイトへリンクします
 |
In Vivo Antibodies | 保存剤も、安定剤、キャリアタンパク質も無添加の、in vivo 研究用に特別に調整された抗体です。 |
 |
Isotype Controls | 抗体特異的シグナルを明確に識別するin vivo投与用のアイソタイプ コントロールです。 |
 |
InVivoSIMTM Antibodies | 薬物の生物学的影響を研究できる手頃な価格の研究グレードのバイオシミラー モノクローナル抗体です。 |
 |
RecombiMAbTM Antibodies | 当社の組換えモノクローナル抗体を使用して、マウスモデルまたはヒト化マウスモデルの免疫原性を低減します。 |
 |
InVivoMAbTM Antibodies | 高品質で高純度の抗体を使用して、in vivo および in vitro アプリケーションの成功を推進します。 |
 |
InVivoPlusTM Antibodies | あらゆる研究機関の生体内研究に必要な厳しい要求と厳格な基準を満たします。 |
 |
InVivoPureTM Dilution Buffers | in vivo 用途向けに特別に配合およびテストされたバッファーにより抗体の安定性を維持します。 |
 |
Fusion Proteins | 超低エンドトキシンレベルの融合タンパク質を使用して、受容体とリガンドの相互作用を調査します。 |
 |
ReadyTagTM Antibodies | ダウンストリームウェスタンブロットやELISAなどのために、in vivoで組換えタンパク質タグに確実に結合します。 |
製品説明・参考情報
| InVivoMAb™ vs. InVivoPlus™ | InVivoMAb™とInVivoPlus™ の違い |
| Biosimilar Antibodies | 研究グレードのバイオシミラー モノクローナル抗体のInVivoSIM™について |
| Recombinant Antibodies | 組換え抗体 RecombiMAb™ モノクローナル抗体について |
| Cell Depletion Antibodies | in vivo用のマウス細胞特異的細胞除去抗体について |
| Immune Checkpoint Antibodies | 免疫チェックポイント経路を標的とする様々な抗体について |
| Choosing Anti-PD-1 Antibodies | 研究に適切な抗 PD-1 抗体を選択する方法 |
| Choosing Isotype Controls | in vivo 実験に適切なアイソタイプ コントロールを選択して使用する方法 |
| Antibody Structure | 抗体の構造と分類について |
よくあるご質問
| Q1. in-vivoの研究に使えますか？ A1. お使いになれます！ |
| Q2. 保存料は入ってますか？ A2. 保存料は入っておりません。 |
| Q3. 在庫はありますか？納期はどれぐらいですか？ A3. 基本的にメーカー在庫はありますが、国内在庫は置いておりません。納期は、ご注文から２～３週間程度頂いてます。早ければ、1週間程度でお納めすることもございます。 |
| Q4. InVivoMabとInVivoPlusの違いは？ A4. InVivoPlusはより厳しい品質を求められる研究に適しています。エンドトキシンの濃度は、InVivoMabが<2EU/mg、InVivoPlusが<1EU/mg です。詳細は下記の比較表をご覧ください。 |
| Q5. 参考文献はありますか？ A5. メーカーの製品概要ページよりご参照ください。”References”の文字をクリックすると一覧が表示されます。 |
| Q6. 1mlサイズの物が欲しいのですが？ A6. BXC社製品は、mg単位での容量となっております（ロットによってタンパク濃度が異なるため）。お手元の製品と同じサイズの物がご入用の場合は、ラベルまたはデータシートの”Total protein”の値をご確認ください。（各製品の容量は価格表をご参照ください。） |
| Q7. 国立の研究所ですが、大学向け価格で買えますか？ A7. 価格表には便宜上、「大学向け」と記していますが、大学及び非営利組織向けの価格となりますので、国公立の研究所・病院などは大学向け価格で販売しております。ご注文の際には、アカデミックプライス適用申込書を都度ご提出ください。なお、代理店経由での販売も致しております。 |
| Q8. 数種類、または複数本買う場合、手数料はどうなりますか？ A8. 一まとめのご注文ごとに1回分のお手数料をご請求いたします。1度のご注文が1本でも、10本でも同じお手数料になりますので、まとめてのご注文をお勧めいたします。 |
| Q9. 抗体の推奨コントロールはどれになりますか？ A9. メーカーの製品概要ページに掲載がございます。「Recomended Isotype Control(s)」をご覧ください。 |
| Q10. 抗体の保存期間はどのくらいですか？ A10. 製品データシートに記載されている条件で抗体を保管した場合、受領日から1年間安定しています。 |
| Q11. BXC社の製品はカルタヘナ法に該当しますか？ A11. BXC社のすべての製品はカルタヘナ法に該当しません。 |
| Q12. 抗体 100mgを1本注文したところ、50mgのバイアルが2本届きました。間違えていませんか？ A12. メーカーの在庫状況により包装形態がご注文と異なる場合がございます。包装サイズのご指定はお受け致しかねますので、予めご了承のほどお願い申し上げます。 例： 100mg x 1本の注文 → 50mg x 1本と25mg x 2本での納品など |
| Q13. 無償サンプルはありますか？ A13. あいにく無償サンプルの提供はございません。 |
InVivoMAb™ vs. InVivoPlus™
Bio X Cell社は、最も人気のある InVivoMAb™ 製品の InVivoPlus™ バージョンを提供しています。 BXC社製品の InVivoPlus™ バージョンは、InVivoMAb™ バージョンと構造的および機能的に同一です。 違いは、あらゆる研究機関の生体内研究に必要な厳しい要求と厳格な基準を満たす、またはそれを超える優れたレベルの品質にあります。
| InVivoMAb™ | InVivoPlus™ | |
| バインディングの検証* Determined by immunoblot, flow cytometry, or ELISA |
未確認 | 確認済 |
| マウス病原体スクリーニング† Determined by ultrasensitive real-time PCR |
未確認 | 確認済 |
| 抗体凝集スクリーニング Determined by Size Exclusion Chromatography |
未確認 | 確認済 |
| エンドトキシン Determined by LAL gel clotting assay |
<2EU/mg | <1EU/mg |
| 純度 Determined by SDS-PAGE |
>95% | >95% |
| 防腐剤、安定剤、キャリアタンパク質不使用 | 不使用 | 不使用 |
| in-vivo 研究の適性 | 適する | 適する |
| 品番 | BEから始まる | BPから始まる |
*バインディングの検証は、該当するすべての InVivoPlus™ 製品のロットごとに実行されます。 適用されない InVivoPlus™ 製品には、抗原が市販されていない抗体や非反応性アイソタイプ コントロール抗体が含まれます。
†マウス病原体スクリーニングは以下を含みます:
Mycoplasma including M. pulmonis, M. arginini, M. fermentans, M. hominis, M. hyorhinis, M. orale, M. pirum, M. salivarium, M. agassizii, M. cynos and others.
Murine norovirus (MNV), murine parvovirus (MPV) 1, 2, 3, 4, and 5, murine minute virus (MMV/MVM), murine hepatitis virus (MHV), murine reovirus (REO) type 1, 2, and 3, lymphocytic choriomeningitis virus (LCMV), lactate dehydrogenase elevating virus (LDV), murine rotavirus MRV/EDIM), Theiler’s murine encephalomyelitis virus (TMEV), ectromelia virus (ECTRO), hantavirus (HANTA), polyoma virus (POLY), murine adenovirus (detects and differentiates MAD1 and MAD2), sendai virus (SEND), pneumonia virus of mice (PVM), murine cytomegalovirus (MCMV) 1 and 2 (MCMV), and K virus.
製品一覧
◎製品検索は表の上の検索ボックスをご利用ください。品番のリンクから製品詳細（Bio X Cell社サイト）をご覧いただけます。
| 新製品 | 品番-最小容量 | 品名 | クローン | イソタイプ | 報告された用途 | 推奨コントロール品番 | 推奨バッファー品番 |
|---|---|---|---|---|---|---|---|
| BE0000-1MG | InVivoMAb anti-mouse CD1d (CD1.1) | 19G11 | IgG1 | in vivo CD1d neutralization, in vitro CD1d neutralization | BE0088 | IP0070 | |
| BE0001-1-1MG | InVivoMAb anti-mouse CD3ε | 145-2C11 | IgG1 | in vivo T cell depletion, in vitro T cell stimulation/activation, Immunofluorescence, Flow cytometry, Western blot | BE0091 | IP0070 | |
| BE0001-1FAB-10MG | InVivoMAb anti-mouse CD3ε F(ab')2 fragment | 145-2C11 f(ab')2 Fragments | IgG1 | in vivo T cell depletion | BE0091-FAB | IP0070 | |
| BE0001-2-1MG | InVivoMAb anti-human CD3 | OKT-3 | IgG2a, κ | in vitro T cell stimulation/activation, in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenografts, Flow cytometry | BE0085 | IP0070 | |
| BE0002-1MG | InVivoMAb anti-mouse CD3 | 17A2 | IgG2b, κ | in vitro T cell stimulation/activation | BE0090 | IP0070 | |
| BE0003-1-1MG | InVivoMAb anti-mouse CD4 | GK1.5 | IgG2b, κ | in vivo CD4+ T cell depletion, Flow cytometry, Western blot | BE0090 | IP0065 | |
| BE0003-2-1MG | InVivoMAb anti-human CD4 | OKT-4 | IgG2b, κ | in vitro T cell stimulation/activation, in vivo CD4+ T cell depletion in humanized mice, Flow cytometry, Immunoprecipitation | BE0086 | IP0070 | |
| BE0003-3-1MG | InVivoMAb anti-mouse CD4 | YTS 177 | IgG2a | in vivo blockade of CD4+ T-cell responses, Western blot | BE0089 | IP0070 | |
| BE0004-1-1MG | InVivoMAb anti-mouse CD8α | 53-6.7 | IgG2a, κ | in vivo CD8+ T cell depletion, Immunofluorescence, Flow cytometry, Western blot | BE0089 | IP0065 | |
| BE0004-2-1MG | InVivoMAb anti-human CD8α | OKT-8 | IgG2a | in vivo CD8+ T cell depletion in humanized mice | BE0085 | IPT060 | |
| BE0005-1MG | InVivoMAb anti-human LFA-1α (CD11a) | TS-1/22.1.1.13 | IgG1 | in vitro LFA-1 neutralization | BE0083 | IP0070 | |
| BE0005-1-1MG | InVivoMAb anti-mouse LFA-1α (CD11a) | FD441.8 | IgG2b | in vivo LFA-1 neutralization | BE0090 | IP0070 | |
| BE0007-1MG | InVivoMAb anti-mouse/human CD11b | M1/70 | IgG2b, κ | in vivo CD11b neutralization, ILC2 cell purification, Flow cytometry | BE0090 | IP0070 | |
| BE0009-1MG | InVivoMAb anti-mouse CD18 | M18/2 | IgG2a, κ | in vivo LFA-1 neutralization | BE0089 | IP0070 | |
| BE0011-1MG | InVivoMAb anti-mouse CD22 | Cy34.1 | IgG1, κ | in vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), Flow cytometry, Immunoprecipitation | BE0083 | IP0070 | |
| BE0012-1MG | InVivoMAb anti-mouse CD25 (IL-2Rα) | PC-61.5.3 | IgG1, λ | in vivo regulatory T cell depletion, Flow cytometry | BE0088 | IP0070 | |
| BE0014-1MG | InVivoMAb anti-human CD25 (IL-2Rα) | 7G7B6 | IgG2a | in vivo regulatory T cell depletion in humanized mice, Immunoprecipitation, Immunofluorescence | BE0085 | IP0070 | |
| BE0015-1-1MG | InVivoMAb anti-mouse CD28 | 37.51 | IgG2 | in vitro T cell stimulation/activation, in vivo CD28 blockade | BE0087 | IPT060 | |
| BE0016-2-1MG | InVivoMAb anti-mouse CD40 | FGK4.5/FGK45 | IgG2a | in vivo CD40 activation, in vitro B cell stimulation/activation | BE0089 | IP0070 | |
| BE0017-1-1MG | InVivoMAb anti-mouse CD40L (CD154) | MR-1 | IgG | in vivo blocking of CD40/CD40L signaling, in vitro blocking of CD40/CD40L signaling, Western blot | BE0091 | IP0070 | |
| BE0019-1MG | InVivoMAb anti-mouse CD45RB | MB23G2 (HB220) | IgG2a, κ | in vivo anti-CD45RB_mediated tolerance induction, in vivo pre-mNK cell depletion | BE0089 | IP0070 | |
| BE0019-1-1MG | InVivoMAb anti-human CD47 | B6.H12 | IgG1, κ | in vitro CD47 neutralization, in vivo CD47 neutralization in human tumor xenograft models or humanized mice, Flow cytometry | BE0083 | IP0070 | |
| BE0020-1-1MG | InVivoMAb anti-mouse CD54 (ICAM-1) | YN1/1.7.4 | IgG2b, κ | in vivo ICAM-1 neutralization, Immunohistochemistry (frozen), ELISA | BE0090 | IP0070 | |
| BE0020-2-1MG | InVivoMAb anti-human CD54 (ICAM-1) | R6-5-D6 | IgG2a | in vitro T cell stimulation/activation, Immunofluorescence | BE0085 | IP0070 | |
| BE0021-1MG | InVivoMAb anti-mouse L-Selectin (CD62L) | Mel-14 | IgG2a, κ | in vivo CD62L neutralization | BE0089 | IP0070 | |
| BE0022-1MG | InVivoMAb anti-mouse CD70 | FR70 | IgG2b, κ | in vivo CD70 blockade, in vitro CD70 blockade, Flow cytometry | BE0090 | IP0070 | |
| BE0023-1MG | InVivoMAb anti-human CD71 | OKT-9 | IgG1, κ | Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry | BE0083 | IP0070 | |
| BE0024-1MG | InVivoMAb anti-mouse CD80 (B7-1) | 16-10A1 | IgG2 | in vivo CD80 blockade, Flow cytometry | BE0091 | IP0080 | |
| BE0025-1MG | InVivoMAb anti-mouse CD86 (B7-2) | GL-1 | IgG2a, κ | in vivo CD86 blockade, Flow cytometry | BE0089 | IP0070 | |
| BE0026-1MG | InVivoMAb anti-mouse CD103 | M290 | IgG2a, κ | in vivo CD103 neutralization, Immunofluorescence, Flow cytometry | BE0089 | IP0070 | |
| BE0027-1MG | InVivoMAb anti-mouse CD106 (VCAM-1) | M/K-2.7 | IgG1, κ | in vivo VCAM-1 neutralization, Immunofluorescence | BE0088 | IP0070 | |
| BE0028-1MG | InVivoMAb anti-mouse ICOSL (CD275) | HK5.3 | IgG2a, κ | in vivo ICOSL neutralization | BE0089 | IP0070 | |
| BE0029-1MG | InVivoMAb anti-mouse IFNγR (CD119) | GR-20 | IgG2a, κ | in vivo IFNγR neutralization, in vitro IFNγR neutralization | BE0089 | IP0070 | |
| BE0031-1MG | InVivoMAb anti-mouse OX40 (CD134) | OX-86 | IgG1, κ | in vivo OX40 activation, in vitro OX40 activation, Western blot | BE0088 | IP0070 | |
| BE0032-1MG | InVivoMAb anti-mouse CTLA-4 (CD152) | UC10-4F10-11 | IgG | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blot | BE0091 | IP0065 | |
| BE0033-1-1MG | InVivoMAb anti-mouse OX40L (CD134L) | RM134L | IgG2b, κ | in vivo blocking of OX40/OX40L signaling, in vitro OX40L neutralization | BE0090 | IP0070 | |
| BE0033-2-1MG | InVivoMAb anti-mouse PD-1 (CD279) | J43 | IgG | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Western blot | BE0091 | IP0065 | |
| BE0034-1MG | InVivoMAb anti-mouse LPAM-1 (Integrin α4β7) | DATK32 | IgG2a, κ | in vivo Integrin α4β7 neutralization, Flow cytometry | BE0089 | IP0070 | |
| BE0035-1MG | InVivoMAb anti-mouse MAdCAM-1 | MECA-367 | IgG2a, κ | in vivo MAdCAM-1 neutralization, Immunofluorescence | BE0089 | IP0070 | |
| BE0036-1MG | InVivoMAb anti-mouse NK1.1 | PK136 | IgG2a, κ | in vivo NK cell depletion, Flow cytometry | BE0085 | IP0070 | |
| BE0039-1MG | InVivoMAb anti-mouse/human CD44 | IM7 | IgG2b, κ | in vivo CD44 neutralization, in vitro CD44 neutralization | BE0090 | IP0070 | |
| BE0040-1MG | InVivoMAb anti-rat CD28 | JJ319 | IgG1, κ | in vitro T cell stimulation/activation, Flow cytometry | BE0083 | IP0070 | |
| BE0042-1MG | InVivoMAb anti-mouse IL-2 | JES6-5H4 | IgG2b, κ | in vivo IL-2 neutralization, in vitro IL-2 neutralization, in vivo IL-2 receptor stimulation (as a complex with IL-2), ELISPOT, Flow cytometry | BE0090 | IP0070 | |
| BE0045-1MG | InVivoMAb anti-mouse IL-4 | 11B11 | IgG1, κ | in vivo IL-4 neutralization, in vitro IL-4 neutralization, in vivo IL-4 receptor stimulation (as a complex with IL-4), Flow cytometry, Western blot | BE0088 | IP0070 | |
| BE0046-1MG | InVivoMAb anti-mouse IL-6 | MP5-20F3 | IgG1, κ | in vivo IL-6 neutralization, in vitro IL-6 neutralization | BE0088 | IP0070 | |
| BE0047-1MG | InVivoMAb anti-mouse IL-6R | 15A7 | IgG2b, κ | in vivo blocking of IL-6/IL-6R signaling, in vitro blocking of IL-6R signaling | BE0090 | IP0070 | |
| BE0048-1MG | InVivoMAb anti-mouse/human IL-7 | M25 | IgG2b | in vivo IL-7 neutralization, in vivo IL-7 receptor stimulation (as a complex with IL-7) | BE0086 | IP0070 | |
| BE0049-1MG | InVivoMAb anti-mouse IL-10 | JES5-2A5 | IgG1, κ | in vivo IL-10 neutralization, in vitro IL-10 neutralization | BE0088 | IP0070 | |
| BE0050-1MG | InVivoMAb anti-mouse IL-10R (CD210) | 1B1.3A | IgG1, κ | in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, Flow cytometry, Western Blot | BE0088 | IPT065 | |
| BE0051-1MG | InVivoMAb anti-mouse IL-12 p40 | C17.8 | IgG2a, κ | in vivo IL-12p40 neutralization, p40 affinity chromatography, Immunoprecipitation, ELISA, Flow cytometry, Western blot | BE0089 | IP0070 | |
| BE0052-1MG | InVivoMAb anti-mouse IL-12 | R1-5D9 | IgG2a | in vivo IL-12 neutralization, in vitro IL-12 neutralization | BE0089 | IP0070 | |
| BE0054-1MG | InVivoMAb anti-mouse IFNγ | R4-6A2 | IgG1, κ | in vivo IFNγ neutralization, in vitro IFNγ neutralization | BE0088 | IP0080 | |
| BE0057-1MG | InVivoMAb anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-β | 1D11.16.8 | IgG1, κ | in vivo TGFβ neutralization, in vitro TGFβ neutralization, Western blot | BE0083 | IP0070 | |
| BE0058-1MG | InVivoMAb anti-mouse TNFα | XT3.11 | IgG1 | in vivo TNFα neutralization, in vitro TNFα neutralization, Western blot | BE0088 | IP0080 | |
| BE0059-1MG | InVivoMAb anti-mouse ICOS | 7E.17G9 | IgG2b, κ | in vivo blocking of ICOS/ICOSL signaling, Flow cytometry | BE0090 | IP0080 | |
| BE0060-1MG | InVivoMAb anti-mouse VEGFR-2 | DC101 | IgG1, κ | in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling, Western blot | BE0088 | IP0070 | |
| BE0061-1MG | InVivoMAb anti-mouse CD8α | 2.43 | IgG2b, κ | in vivo CD8+ T cell depletion, Western blot | BE0090 | IP0070 | |
| BE0062-1MG | InVivoMAb anti-mouse/human Integrin β7 | FIB504 | IgG2a, κ | in vivo blocking of integrin β7, Immunoprecipitation, Western blot, Flow cytometry | BE0089 | IP0070 | |
| BE0063-1MG | InVivoMAb anti-mouse GITR | DTA-1 | IgG2b, λ | in vivo GITR stimulation | BE0090 | IP0070 | |
| BE0065-1MG | InVivoMAb anti-mouse IL-7Rα (CD127) | A7R34 | IgG2a, κ | in vivo blocking of IL-7Rα signaling, Flow cytometry | BE0089 | IP0070 | |
| BE0066-1MG | InVivoMAb anti-mouse Thy1.2 (CD90.2) | 30H12 | IgG2b, κ | in vivo ILC depletion, in vivo T cell depletion, Western blot | BE0090 | IP0070 | |
| BE0067-1MG | InVivoMAb anti-mouse B220 | RA3.3A1/6.1 (TIB-146) | Rat IgM | in vivo B cell depletion, in vitro B cell negative selection | BE0094 | IP0070 | |
| BE0068-1MG | InVivoMAb anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) | 10-3.6.2 | IgG2c, κ | in vitro MHC class II I-A blocking, in vitro MHC class II I-A expressing cell negative selection | BE0366 | IP0070 | |
| BE0069-1MG | InVivoMAb anti-mouse 2C TCR | 1B2 | IgG1 | Immunofluorescence, Flow cytometry | BE0083 | IP0070 | |
| BE0070-1MG | InVivoMAb anti-mouse TCR γ/δ | UC7-13D5 | IgG, κ | in vivo TCR γ/δ neutralization, in vitro γ/δ T cell stimulation, in vitro γ/δ T cell purification, Functional assays, Immunoprecipitation, Flow cytometry | BE0091 | IPT060 | |
| BE0071-1MG | InVivoMAb anti-mouse/human VLA-4 (CD49d) | PS/2 | IgG2b, κ | in vivo VLA-4 neutralization, in vitro VLA-4 neutralization, Flow cytometry | BE0090 | IP0065 | |
| BE0072-1MG | InVivoMAb anti-mouse T15 VH and T15 VL regions of IgM | AB1-2 (HB33) | IgG1, κ | ELISA | BE0083 | IP0070 | |
| BE0075-1MG | InVivoMAb anti-mouse Ly6G/Ly6C (Gr-1) | RB6-8C5 | IgG2b, κ | in vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | BE0090 | IP0070 | |
| BE0075-1-1MG | InVivoMAb anti-mouse Ly6G | 1A8 | IgG2a, κ | in vivo neutrophil depletion, in vivo MDSC depletion, Immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry | BE0089 | IP0070 | |
| BE0076-1MG | InVivoMAb anti-mouse Thy1 (CD90) | M5/49.4.1 | IgG2a | in vitro T cell depletion | BE0089 | IP0070 | |
| BE0077-1MG | InVivoMAb anti-mouse MHC Class I (H-2) | M1/42.3.9.8 | IgG2a, κ | ex vivo blocking of MHC I-dependent interactions, Immunofluorescence, Flow cytometry | BE0089 | IP0070 | |
| BE0079-1MG | InVivoMAb anti-human MHC Class I (HLA-A, HLA-B, HLA-C) | W6/32 | IgG2a, κ | Functional assays | BE0085 | IP0065 | |
| BE0083-1MG | InVivoMAb mouse IgG1 isotype control, unknown specificity | MOPC-21 | IgG1, κ | IP0065 | |||
| BE0085-1MG | InVivoMAb mouse IgG2a isotype control, unknown specificity | C1.18.4 | IgG2a, κ | IP0070 | |||
| BE0086-1MG | InVivoMAb mouse IgG2b isotype control, unknown specificity | MPC-11 | IgG2b, κ | IP0070 | |||
| BE0087-1MG | InVivoMAb polyclonal Syrian hamster IgG | polyclonal Syrian hamster IgG | IgG | IP0070 | |||
| BE0088-1MG | InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase | HRPN-CP167 | IgG1, κ | IP0070 | |||
| BE0089-1MG | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol | 2A3 | IgG2a, κ | IP0065 | |||
| BE0090-1MG | InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin | LTF-2-CP166 | IgG2b, κ | IP0070 | |||
| BE0091-1MG | InVivoMAb polyclonal Armenian hamster IgG | polyclonal Armenian hamster IgG | IgG | IP0070 | |||
| BE0091-FAB-10MG | InVivoMAb hamster IgG f(ab')2 fragments | hamster IgG f(ab')2 Fragments | Polyclonal | IP0070 | |||
| BE0092-1MG | InVivoMAb polyclonal human IgG | polyclonal human IgG | IgG | IP0070 | |||
| BE0093-1MG | InVivoMAb polyclonal mouse IgG | polyclonal mouse IgG | IgG | IP0070 | |||
| BE0094-1MG | InVivoMAb polyclonal rat IgG | polyclonal rat IgG | IgG | IP0070 | |||
| BE0096-1MG | InVivoMAb recombinant human IgG1 Fc | human Fc-G1 | IP0070 | ||||
| BE0097-1MG | InVivoMAb recombinant mouse IgG2a Fc | Mouse Fc-G2a | IP0070 | ||||
| BE0098-1MG | InVivoMAb recombinant Flt-3L-Ig (hum/hum) | Flt-3L-Ig (hum/hum) | BE0096 | IP0070 | |||
| BE0099-1MG | InVivoMAb recombinant CTLA-4-Ig (hum/hum) | CTLA-4-Ig (hum/hum) | BE0096 | IP0070 | |||
| BE0101-1MG | InVivoMAb anti-mouse PD-L1 (B7-H1) | 10F.9G2™ | IgG2b, κ | in vivo PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry, Western blot | BE0090 | IP0065 | |
| BE0102-1MG | InVivoMAb anti-mouse TCRβ | H57-597 (HB218) | IgG | in vivo T cell depletion | BE0091 | IP0070 | |
| BE0104-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kd) | SF1.1.10 (HB-159) | IgG2a, κ | Purification of MHC peptide complexes, in vivo administration, Flow cytometry | BE0085 | IP0070 | |
| BE0106-1MG | InVivoMAb anti-LCMV nucleoprotein | VL-4 | IgG2a, κ | Immunofluorescence, Flow cytometry | BE0089 | IP0070 | |
| BE0108-1MG | InVivoMAb anti-mouse MHC Class II (I-A/I-E) | M5/114 | IgG2b | in vivo MHC II blockade, Functional assays, Immunofluorescence, Western blot, Immunoprecipitation, Flow cytometry | BE0090 | IP0070 | |
| BE0110-1MG | InVivoMAb anti-mouse 4-1BBL (CD137L) | TKS-1 | IgG2a, κ | in vivo 4-1BBL blockade, ELISA | BE0089 | IP0070 | |
| BE0111-1MG | InVivoMAb anti-mouse NKG2D | HMG2D | IgG | in vivo NKG2D blockade | BE0091 | IP0070 | |
| BE0112-1MG | InVivoMAb anti-mouse PD-L2 (B7-DC) | TY25 | IgG2a, κ | in vivo PD-L2 blockade, in vitro PD-L2 blockade, Immunohistochemistry (frozen), Flow cytometry | BE0089 | IP0070 | |
| BE0113-1MG | InVivoMAb anti-mouse TIM-1 (CD365) | RMT1-10 | IgG2a, κ | in vivo TIM-1 blockade | BE0089 | IP0070 | |
| BE0114-1MG | InVivoMAb anti-mouse TIM-2 | RMT2-29 | Rat Ig2a, λ | BE0089 | IP0070 | ||
| BE0115-1MG | InVivoMAb anti-mouse TIM-3 (CD366) | RMT3-23 | IgG2a, κ | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometry | BE0089 | IP0070 | |
| BE0117-1MG | InVivoMAb anti-mouse CD8α | YTS 169.4 | IgG2b, κ | in vivo CD8+ T cell depletion, Western blot | BE0090 | IP0070 | |
| BE0118-1MG | InVivoMAb anti-mouse CD8 (Lyt 2.1) | 116-13.1 (HB-129) | IgG2a, κ | in vivo CD8+ T cell depletion, Flow cytometry | BE0085 | IP0070 | |
| BE0119-1MG | InVivoMAb anti-mouse CD4 | YTS 191 | IgG2b, κ | in vivo CD4+ T cell depletion | BE0090 | IP0070 | |
| BE0120-1MG | InVivoMAb anti-swine MHC Class I (SLAd) | 74-11-10 (HB139) | IgG2b, κ | Flow cytometry | BE0086 | IP0070 | |
| BE0121-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kb) | AF6-88.5.5.3 | IgG2a, κ | in vivo administration, Flow cytometry | BE0085 | IP0070 | |
| BE0122-1MG | InVivoMAb anti-rat Kappa Immunoglobulin Light Chain | MAR 18.5 | IgG2a, κ | in vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-CD22 (clone Cy34.1) | BE0085 | IP0070 | |
| BE0123-1MG | InVivoMAb anti-human/rat/fish AChR | Mab35 (TIB-175) | IgG1 | EAMG induction in rats, Immunofluorescence | BE0088 | IP0070 | |
| BE0124-1MG | InVivoMAb anti-mouse CD276 (B7-H3) | MJ18 | IgG1, κ | in vivo B7-H3 blockade, Flow cytometry | BE0088 | IP0070 | |
| BE0125-1MG | InVivoMAb anti-mouse Jagged 2 | HMJ2-1 | IgG | in vivo Jagged 2 neutralization | BE0091 | IP0070 | |
| BE0127-1MG | InVivoMAb anti-mouse Delta-like protein 4 (DLL4) | HMD4-2 | IgG, κ | in vivo DLL4 neutralization, in vitro DLL4 neutralization | BE0091 | IP0070 | |
| BE0129-1MG | InVivoMAb anti-mouse Notch4 | HMN4-14 | IgG, κ | in vivo Notch4 blocking, in vitro Notch4 stimulation, Flow cytometry | BE0091 | IP0070 | |
| BE0131-1MG | InVivoMAb anti-mouse CTLA-4 (CD152) | 9H10 | IgG | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Western blot | BE0087 | IP0070 | |
| BE0132-1MG | InVivoMAb anti-mouse BTLA (CD272) | 6A6 | IgG, κ | in vivo BTLA stimulation, in vivo BTLA blockade | BE0091 | IP0070 | |
| BE0134-1MG | InVivoMAb anti-mouse CD80 (B7-1) | 1G10 | IgG2a, κ | in vivo CD80 blockade, Affinity chromatography | BE0089 | IP0070 | |
| BE0136-1MG | InVivoMAb anti-human E-Selectin | CL2 | IgG2a, κ | Flow cytometry | BE0085 | IP0070 | |
| BE0139-1MG | InVivoMAb anti-mouse/human/rat v-H-Ras | Y13-238 | IgG2a | Immunoprecipitation | BE0089 | IP0070 | |
| BE0140-1MG | InVivoMAb anti-mouse MHC Class II (βchain) | KL277 | IgG | Western blot | IP0070 | ||
| BE0143-1MG | InVivoMAb anti-rat β-2-Microglobulin | 4C9 | IgG1 | in vitro β2M blockade | BE0083 | IP0070 | |
| BE0144-1MG | InVivoMAb anti-rat FcRn heavy chain heterodimers | 2G3 | IgG1 | ELISA, Flow cytometry | BE0083 | IP0070 | |
| BE0146-1MG | InVivoMAb anti-mouse PD-1 (CD279) | RMP1-14 | IgG2a, κ | in vivo blocking of PD-1/PD-L signaling | BE0089 | IP0070 | |
| BE0147-1MG | InVivoMAb anti-mouse CD48 | HM48-1 | IgG | in vivo CD48 blockade, in vitro CD48 blocking | BE0091 | IP0070 | |
| BE0150-1MG | InVivoMAb anti-mouse CD19 | 1D3 | IgG2a, κ | in vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, Flow cytometry | BE0089 | IP0070 | |
| BE0151-1MG | InVivoMAb anti-mouse/human TYRP1/TRP1 (gp75) | TA99 | IgG2a, κ | in vivo triggering of FcγRs, Immunofluorescence, Flow cytometry | BE0085 | IP0070 | |
| BE0152-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kk) | AF3-12.1.3 | IgG1 | in vivo administration | BE0083 | IP0070 | |
| BE0153-1MG | InVivoMAb anti-mouse BTLA (CD272) | PK18.6 | IgG1, κ | in vivo stimulation of BTLA, in vitro stimulation of BTLA, Flow cytometry | BE0088 | IP0070 | |
| BE0154-1MG | InVivoMAb anti-HIV gp120 | 55-36 | IgG1, κ | BE0083 | IP0070 | ||
| BE0155-1MG | InVivoMAb anti-mouse Delta-like protein 1 (DLL1) | HMD1-5 | IgG, κ | in vivo DLL1 neutralization, Flow cytometry | BE0091 | IP0070 | |
| BE0158-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk) | 15-3-1S (HB-13) | IgG2a, κ | in vivo administration, Flow cytometry | BE0085 | IP0070 | |
| BE0159-1MG | InVivoMAb anti-Influenza A virus NP | H16-L10-4R5 (HB-65) | IgG2a | Immunoprecipitation, Immunohistochemistry (paraffin), in vivo induction of passive immunity to influenza A virus, Western blot, Flow cytometry | BE0085 | IP0070 | |
| BE0161-1MG | InVivoMAb anti-mouse DR5 (CD262) | MD5-1 | IgG, κ | in vivo induction TRAIL-mediated apoptosis, in vitro induction TRAIL-mediated apoptosis | BE0091 | IP0070 | |
| BE0162-1MG | InVivoMAb anti-human Glycophorin A (type M) | 6A7M | IgG1, κ | in vitro GPA blockade | BE0083 | IP0070 | |
| BE0164-1MG | InVivoMAb anti-mouse CTLA-4 (CD152) | 9D9 | IgG2b | in vivo CTLA-4 neutralization, Western blot | BE0086 | IP0070 | |
| BE0165-1MG | InVivoMAb anti-mouse Nonclassical MHC Class I molecule Qa-1b | 4C2.4A7.5H11 | IgG1 | Western blot, Immunofluorescence | BE0083 | IP0070 | |
| BE0166-1MG | InVivoMAb anti-mouse Vβ4 TCR | KT4 | IgG2b | in vivo administration, Flow cytometry | BE0090 | IP0070 | |
| BE0167-1MG | InVivoMAb anti-mouse/rat MHC Class II (I-Ek/RT1-D) | 14-4-4S (HB-32) | IgG2a, κ | in vivo blocking of antigen presentation, Flow cytometry | BE0085 | IP0070 | |
| BE0168-1MG | InVivoMAb anti-mouse Vγ2 TCR | UC3-10A6 | IgG, κ | in vivo γδ T cell depletion, Flow cytometry | BE0091 | IP0070 | |
| BE0169-1MG | InVivoMAb anti-mouse 4-1BB (CD137) | LOB12.3 | IgG1, κ | in vivo activation of 4-1BB | BE0088 | IP0080 | |
| BE0171-1MG | InVivoMAb anti-mouse TIM-4 | RMT4-53 | IgG2b, κ | in vivo TIM-4 blockade, in vitro TIM-4 blockade, Immunofluorescence | BE0090 | IP0070 | |
| BE0172-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kb) | Y-3 | IgG2b, κ | in vivo MHC II blockade, Functional assays, Purification of MHC peptide complexes, Flow cytometry | BE0086 | IP0070 | |
| BE0173-1MG | InVivoMAb anti-mouse IL-17A | 17F3 | IgG1, κ | in vivo IL-17A neutralization | BE0083 | IP0070 | |
| BE0174-1MG | InVivoMAb anti-mouse LAG-3 | C9B7W | IgG1, κ | in vivo LAG-3 neutralization, in vitro LAG-3 neutralization, Flow cytometry, Western blot | BE0088 | IP0070 | |
| BE0175-1MG | InVivoMAb anti-mouse CD71 (TfR1) | R17 217.1.3/TIB-219 | IgG2a, κ | in vivo depletion of CD71+ cells | BE0089 | IP0070 | |
| BE0176-1MG | InVivoMAb anti-mouse Kappa Immunoglobulin Light Chain | 187.1 (HB-58) | IgG1, κ | Immunofluorescence | BE0088 | IP0070 | |
| BE0178-1MG | InVivoMAb anti-mouse MHC class II (I-A) | Y-3P | IgG2a, κ | in vivo blockade of TCR stimulation, Flow cytometry | BE0085 | IP0070 | |
| BE0179-1MG | InVivoMAb anti-mouse CD1d (CD1.1) | 20H2 (HB323) | IgG1, κ | iNKT cell neutralization, in vivo CD1d blockade, Flow cytometry | BE0088 | IP0070 | |
| BE0180-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kd, H-2Dd) | 34-1-2S | IgG2a, κ | in vivo activation of APCs | BE0085 | IP0070 | |
| BE0181-1MG | InVivoMAb anti-mouse IL-9 | 9C1 | IgG2a | in vivo IL-9 neutralization | BE0085 | IP0070 | |
| BE0182-1MG | InVivoMAb anti-mouse Vβ8 TCR | F23.1 | IgG2a, κ | Flow cytometry | BE0085 | IP0070 | |
| BE0183-1MG | InVivoMAb anti-mouse Ter-119 | TER-119 | IgG2b, κ | in vivo administration, in vitro erythrocyte negative selection, Functional assays, Flow cytometry | BE0090 | IP0070 | |
| BE0185-1MG | InVivoMAb anti-mouse/human/rat CCL2 (MCP-1) | 2H5 | IgG, κ | in vivo CCL2 neutralization, Immunohistochemistry (frozen) | BE0091 | IP0070 | |
| BE0186-1MG | InVivoMAb anti-mouse PSGL-1 (CD162) | 4RA10 | IgG1, κ | in vivo PSGL-1 blockade, Immunohistochemistry (frozen) | BE0088 | IP0070 | |
| BE0187-1MG | InVivoMAb anti-rat CD80 (B7-1) | 3H5 | IgG1, κ | in vitro CD80 blockade, Flow cytometry | BE0083 | IP0070 | |
| BE0188-1MG | InVivoMAb anti-human PD-1 (CD279) | J116 | IgG1, κ | in vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice | BE0083 | IP0070 | |
| BE0189-1MG | InVivoMAb anti-human CD40 | G28.5 | IgG1, κ | in vitro CD40 stimulation, Functional assays, Flow cytometry | BE0083 | IP0070 | |
| BE0190-1MG | InVivoMAb anti-human CTLA-4 (CD152) | BN13 | IgG2a, κ | in vitro CTLA-4 neutralization, Flow cytometry | BE0085 | IP0070 | |
| BE0191-1MG | InVivoMAb anti-mouse RANKL (CD254) | IK22/5 | IgG2a, κ | in vivo RANKL blockade | BE0089 | IP0065 | |
| BE0192-1MG | InVivoMAb anti-human CD11a (LFA-1α) | R7-1 | IgG1 | Functional assays, Flow cytometry | BE0083 | IP0070 | |
| BE0193-1MG | InVivoMAb anti-human PD-1 (CD279) | J110 | IgG1, κ | in vivo PD-1 blockade in humanized mice, Flow cytometry | BE0083 | IP0070 | |
| BE0194-1MG | InVivoMAb anti-Phosphotyrosine | 4G10 | IgG2b | ELISA, Western blot | BE0086 | IP0070 | |
| BE0196-1MG | InVivoMAb anti-mouse BTLA (CD272) | PJ196 | IgG1 | in vivo BTLA blockade, in vitro T cell stimulation/activation, Flow cytometry | BE0083 | IP0070 | |
| BE0198-1MG | InVivoMAb anti-mouse/human IL-5 | TRFK5 | IgG1, κ | in vivo IL-5 neutralization, in vivo eosinophil depletion | BE0088 | IP0070 | |
| BE0199-1MG | InVivoMAb anti-mouse IL-4 | BVD6-24G2 | IgG1, κ | ELISA, ELISPOT, Flow cytometry | BE0088 | IP0070 | |
| BE0200-1MG | InVivoMAb anti-mouse Pan-endothelial Cell Antigen (MECA-32) | MECA-32 | IgG2a, κ | Immunohistochemistry (frozen), Flow cytometry, Western blot, Immunofluorescence | BE0089 | IP0070 | |
| BE0201-1MG | InVivoMAb anti-mouse/human KLRG-1 | 2F1 | IgG | Flow cytometry | BE0087 | IP0070 | |
| BE0202-1MG | InVivoMAb anti-mouse Siglec-H | 440c | IgG2b | in vivo administration, Flow cytometry | BE0090 | IP0070 | |
| BE0203-1MG | InVivoMAb anti-mouse Ly6C | Monts 1 | IgG2a | in vivo macrophage depletion (in combination with clodronate liposomes), Flow cytometry | BE0089 | IP0070 | |
| BE0204-1MG | InVivoMAb anti-mouse CSF1 | 5A1 | IgG1, κ | in vivo CSF1 neutralization | BE0088 | IP0080 | |
| BE0206-1MG | InVivoMAb anti-mouse F4/80 | CI:A3-1 | IgG2b, κ | in vivo Monocyte/Macrophage depletion, Functional assays, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry | BE0090 | IP0070 | |
| BE0207-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kb) bound to SIINFEKL peptide (OVA residues 257-264) | 25-D1.16 | IgG1, κ | in vivo blocking of Kb -SIINFEKL, Functional assays, Flow cytometry | BE0083 | IP0070 | |
| BE0209-1MG | InVivoMAb anti-mouse CD73 | TY/23 | IgG2a, κ | in vivo CD73 blockade, in vitro CD73 blockade | BE0089 | IP0070 | |
| BE0210-1MG | InVivoMAb anti-mouse BTLA (CD272) | 8F4 | IgG1, κ | Flow cytometry | BE0083 | IP0070 | |
| BE0211-1MG | InVivoMAb anti-human CD1a | OKT-6 | IgG1 | in vitro CD1a blockade, Flow cytometry | BE0083 | IP0070 | |
| BE0213-1MG | InVivoMAb anti-mouse CSF1R (CD115) | AFS98 | IgG2a, κ | in vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, Flow cytometry, Western blot | BE0089 | IP0070 | |
| BE0214-1MG | InVivoMAb anti-mouse Thy1.1 (CD90.1) | 19E12 | IgG2a, κ | in vivo T cell depletion | BE0085 | IP0070 | |
| BE0216-1MG | InVivoMAb anti-human YB-1 | 21A3 | IgG1 | Immunohistochemistry (paraffin), Western blot | BE0083 | IP0070 | |
| BE0218-1MG | InVivoMAb anti-mouse Galectin-9 | RG9-1 | IgG2b, κ | in vivo Galectin-9 blockade in vitro Galectin-9 blockade | BE0090 | IP0070 | |
| BE0220-1MG | InVivoMAb anti-mouse CD209b (SIGN-R1) | 22D1 | IgG, κ | in vivo SIGN-R1 blockade, Immunohistochemistry (frozen), Western blot, , Flow cytometry | BE0091 | IP0070 | |
| BE0222-1MG | InVivoMAb anti-rat FcRn heavy chain heterodimers | 1G3 | IgG1 | Immunofluorescence, ELISA, Flow cytometry | BE0083 | IP0070 | |
| BE0223-1MG | InVivoMAb anti-mouse CD8β (Lyt 3.2) | 53-5.8 | IgG1, κ | in vivo CD8+ T cell depletion, in vitro CD8 blockade, Immunofluorescence | BE0088 | IP0070 | |
| BE0224-1MG | InVivoMAb anti-human CD32 (FcγRIIA) | IV.3 | IgG2b | in vivo FcγRIIA blockade in humanized mice, in vitro FcγRIIA blockade, ELISA, , Flow cytometry | BE0086 | IP0070 | |
| BE0225-1MG | InVivoMAb anti-mouse TIM-4 | RMT4-54 | IgG2a, κ | in vitro TIM-4 blocking, Immunofluorescence, Flow cytometry | BE0089 | IP0070 | |
| BE0228-1MG | InVivoMAb anti-mouse MHC Class I (H-2Kk, H-2Dk) | 16-1-2N (HB14) | IgG2a | Functional assays, Flow cytometry | BE0085 | IP0070 | |
| BE0231-1MG | InVivoMAb anti-human CD3 | UCHT1 (Leu-4) (T3) | IgG1, κ | in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, Flow cytometry | BE0083 | IP0070 | |
| BE0232-1MG | InVivoMAb anti-mouse CD29 | KMI6 | IgG2a, κ | in vitro CD29 neutralization, Immunofluorescence, Flow cytometry | BE0089 | IP0070 | |
| BE0233-1MG | InVivoMAb anti-mouse IL-12 p75 | R2-9A5 | IgG2b, κ | in vivo IL-12p75 neutralization, ELISA | BE0090 | IP0080 | |
| BE0234-1MG | InVivoMAb anti-human IL-12 p70 | 20C2 | IgG1, κ | Functional assays, ELISA, Flow cytometry | BE0088 | IP0070 | |
| BE0235-1MG | InVivoMAb anti-human IFNγ | B133.5 | IgG1 | in vivo IFNγ neutralization in humanized mice, in vitro IFNγ neutralization | BE0083 | IP0070 | |
| BE0236-1MG | InVivoMAb anti-mouse Podoplanin (gp38) | 8.1.1 | IgG | in vivo PDPN blockade, in vitro PDPN blockade, Immunofluorescence, Western blot, Flow cytometry | BE0087 | IP0070 | |
| BE0237-1MG | InVivoMAb anti-mouse IL-18 | YIGIF74-1G7 | IgG2a, κ | in vivo IL-18 neutralization, in vitro IL-18 neutralization | BE0089 | IP0070 | |
| BE0238-1MG | InVivoMAb anti-human c-myc | 9E10 | IgG1 | Western blot, ELISA, Immunoprecipitation, Flow cytometry | BE0083 | IP0070 | |
| BE0239-1MG | InVivoMAb anti-mouse 4-1BB (CD137) | 3H3 | IgG2a | in vivo 4-1BB stimulation, in vitro 4-1BB stimulation | BE0089 | IP0070 | |
| BE0240-1MG | InVivoMAb anti-human IL-4 | MP4-25D2 | IgG1, κ | in vitro IL-4 neutralization, Flow cytometry | BE0088 | IP0070 | |
| BE0241-1MG | InVivoMAb anti-mouse IFNAR-1 | MAR1-5A3 | IgG1, κ | in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade, Western blot | BE0083 | IP0070 | |
| BE0243-1MG | InVivoMAb anti-mouse IL-1α | ALF-161 | IgG | in vivo IL-1α neutralization, in vitro IL-1α neutralization | BE0091 | IP0070 | |
| BE0244-1MG | InVivoMAb anti-mouse/rat/rabbit TNFα | TN3-19.12 | IgG, κ | in vivo TNFα neutralization, Flow cytometry | BE0091 | IP0070 | |
| BE0245-1MG | InVivoMAb anti-human IFNγ | B27 | IgG1 | Flow cytometry | BE0083 | IP0070 | |
| BE0246-1MG | InVivoMAb anti-mouse/rat IL-1β | B122 | IgG | in vivo IL-1β neutralization, in vitro IL-1β neutralization, ELISA | BE0091 | IP0070 | |
| BE0247-1MG | InVivoMAb anti-mouse TNFR2 (CD120b) | TR75-54.7 | IgG | in vivo TNFR2 blockade, in vitro TNFR2 blockade | BE0091 | IP0070 | |
| BE0248-1MG | InVivoMAb anti-human CD28 | 9.3 | IgG2a | in vitro T cell stimulation/activation | BE0085 | IP0070 | |
| BE0249-1MG | InVivoMAb anti-mouse CXCR3 (CD183) | CXCR3-173 | IgG | in vivo CXCR3 neutralization, Flow cytometry | BE0091 | IP0070 | |
| BE0250-1MG | InVivoMAb anti-rat IgG1 | RG11/39.4 | IgG2c, κ | Flow cytometry | BE0366 | IP0070 | |
| BE0251-1MG | InVivoMAb anti-rat IgG2a | RG7/1.30 | IgG2b, κ | Immunofluorescence, ELISA, Flow cytometry | BE0086 | IP0070 | |
| BE0252-1MG | InVivoMAb anti-rat IgG2b | RG7/11.1 | IgG2b, κ | ELISA, Flow cytometry | BE0086 | IP0070 | |
| BE0256-1MG | InVivoMAb anti-mouse IL-1 R (CD121a) | JAMA-147 | IgG, κ | in vivo IL-1 R blockade, in vitro IL-1 R blockade | BE0091 | IPT060 | |
| BE0257-1MG | InVivoMAb anti-mouse TCR Vγ1.1/Cr4 | 2.11 | IgG | in vivo Vγ1 TCR+ cell depletion, Flow cytometry | BE0091 | IP0070 | |
| BE0258-1MG | InVivoMAb anti-mouse IL-21R | 4A9 | IgG2a, κ | in vivo IL-21R blockade | BE0089 | IP0070 | |
| BE0259-1MG | InVivoMAb anti-mouse GM-CSF | MP1-22E9 | IgG2a, κ | in vivo GM-CSF neutralization, in vitro GM-CSF neutralization, Flow cytometry | BE0089 | IP0070 | |
| BE0260-1MG | InVivoMAb Armenian hamster IgG isotype control, anti-glutathione S-transferase | PIP | IgG | IP0070 | |||
| BE0261-1MG | InVivoMAb anti-mouse CD3ε | KT3 | IgG2a | in vitro T cell negative selection, in vitro T cell stimulation/activation, Immunofluorescence | BE0089 | IP0070 | |
| BE0262-1MG | InVivoMAb anti-human CD44 | Hermes-1 | IgG2a, κ | in vivo CD44 blockade in xenografts, in vitro CD44 blockade, Western blot, Immunofluorescence | BE0089 | IP0070 | |
| BE0270-1MG | InVivoMAb anti-mouse CD47 (IAP) | MIAP301 | IgG2a, κ | in vivo CD47 blockade, in vitro CD47 blockade, Immunofluorescence | BE0089 | IP0070 | |
| BE0271-1MG | InVivoMAb anti-mouse CD132 (common γ chain) | 3E12 | IgG2b | in vivo γc blockade, Functional assays, Immunoprecipitation, Flow cytometry | BE0090 | IP0070 | |
| BE0272-1MG | InVivoMAb anti-mouse CD122 (IL-2Rβ) | 5H4 | IgG2a, κ | in vitro NK cell negative selection, Immunoprecipitation, Flow cytometry | BE0089 | IP0070 | |
| BE0273-1MG | InVivoMAb anti-mouse PD-1 (CD279) | 29F.1A12™ | IgG2a | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Immunohistochemistry (frozen), Immunofluorescence, Western blot, Flow cytometry | BE0089 | IP0070 | |
| BE0274-1MG | InVivoMAb anti-mouse TIGIT | 1G9 | IgG1, κ | in vivo TIGIT stimulation, Flow cytometry | BE0083 | IP0070 | |
| BE0275-1MG | InVivoMAb anti-mouse TIM-3 (CD366) | B8.2C12 | IgG1, κ | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometry | BE0088 | IP0070 | |
| BE0276-1MG | InVivoMAb anti-human/monkey CD20 | 2H7 | IgG2b, κ | in vivo B cell depletion in hCD20 Tg mice, Immunohistochemistry (frozen), Immunoprecipitation, Flow cytometry | BE0086 | IP0070 | |
| BE0277-1MG | InVivoMAb anti-human/rat HER2 (neu) | 7.16.4 | IgG2a, κ | in vivo HER2/neu inhibition, in vitro HER2/neu inhibition, Immunoprecipitation, Immunofluorescence, Flow cytometry | BE0085 | IP0070 | |
| BE0278-1MG | InVivoMAb anti-human EGFR | 225 (HB-8508) | IgG1 | in vitro EGFR blockade, in vivo EGFR blockade in xenografts, Western blot, Functional assays | BE0083 | IP0070 | |
| BE0280-1MG | InVivoMAb anti-mouse c-Kit (CD117) | 2B8 | IgG2b, κ | Flow cytometry, Immunofluorescence, Immunohistochemistry | BE0090 | IP0070 | |
| BE0281-1MG | InVivoMAb anti-human CD19 | 4G7 | IgG1 | Flow cytometry, Functional assays, Immunofluorescence, Chimeric antigen receptor construction (see Poirot, L., et al. reference) | BE0083 | IP0070 | |
| BE0282-1MG | InVivoMab anti-mouse IL-3 | MP2-8F8 | IgG1 | in vivo IL-3 neutralization, in vitro IL-3 neutralization, in vivo IL-3 receptor stimulation (as a complex with IL-3), ELISA, Flow cytometry | BE0088 | IP0065 | |
| BE0283-1MG | InVivoMAb anti-mouse/human/rat CD47 (IAP) | MIAP410 | IgG1, κ | in vivo CD47 blockade, in vitro CD47 blocking, Immunofluorescence | BE0083 | IP0070 | |
| BE0285-1MG | InVivoMAb anti-human PD-L1 (B7-H1) | 29E.2A3 | IgG2b, κ | in vitro PD-L1 blockade, Functional assays, Immunohistochemistry (frozen), Flow cytometry | BE0086 | IP0070 | |
| BE0287-1MG | InVivoMAb anti-mouse IFNγRα (CD119) | 2E2 | IgG | Western blot, Immunoprecipitation, Flow cytometry | BE0091 | IP0070 | |
| BE0288-1MG | InVivoMAb anti-human CD4 | RPA-T4 | IgG1, κ | in vitro CD4 blockade, in vitro blocking of CD4+ T cell activation, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry | BE0083 | IP0070 | |
| BE0289-1MG | InVivoMAb anti-mouse TIM-1 (CD365) | 3B3 | IgG2a, κ | in vivo TIM-1 activation, in vitro T cell stimulation/activation, Functional assays, ELISA, Flow cytometry | BE0089 | IP0070 | |
| BE0290-1MG | InVivoMAb rat IgG1 Isotype control, anti-trinitrophenol | TNP6A7 | IgG1, λ | IP0070 | |||
| BE0291-1MG | InVivoMAb anti-human/monkey CD28 | CD28.2 | IgG1, κ | in vitro T cell stimulation/activation, Immunoprecipitation, Flow cytometry, Immunohistochemistry (frozen) | BE0083 | IP0070 | |
| BE0292-1MG | InVivoMAb anti-human/monkey CD40L (CD154) | 5C8 | IgG2a | in vitro blocking of CD40/CD40L signaling, in vivo blocking of CD40/CD40L signaling, Immunoprecipitation, Flow cytometry | BE0085 | IP0070 | |
| BE0293-1MG | InVivoMAb anti-mouse c-Kit (CD117) | ACK2 | IgG2b | in vivo mast cell depletion, in vivo c-Kit+ cell depletion, in vitro c-Kit neutralization, Immunoprecipitation, Flow cytometry | BE0090 | IP0070 | |
| BE0294-1MG | InVivoMAb anti-mouse E-selectin (CD62E) | 9A9 | IgG2b | in vivo E-selectin blockade, in vitro E-selectin blockade, Immunohistochemistry (frozen) | BE0090 | IP0070 | |
| BE0296-1MG | InVivoMAb anti-mouse 4-1BB (CD137) | 17B5 | IgG | in vitro 4-1BB blockade, Flow cytometry | BE0087 | IP0070 | |
| BE0297-1MG | InVivoMAb human IgG1 isotype control | human IgG1 | IgG1, κ | IP0070 | |||
| BE0298-1MG | InVivoMAb anti-mouse CD122 (IL-2Rβ) | TM-Beta 1 | IgG2b, κ | in vivo NK cell depletion, in vivo CD122 blockade, in vitro IL-2R blockade, Functional assays, Flow cytometry | BE0090 | IP0080 | |
| BE0299-1MG | InVivoMAb anti-mouse CD200 (OX2) | OX-90 | IgG2a, κ | in vivo CD200 blockade, in vitro CD200 blockade, Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry | BE0089 | IP0070 | |
| BE0300-1MG | InVivoMAb anti-mouse CD45.2 | 104.2 | IgG2a, κ | Flow cytometry, in vivo CD45.2 blockade, in vitro CD45.2 blockade, Immunohistochemistry (frozen) | BE0085 | IP0070 | |
| BE0301-1MG | InVivoMAb human IgG2 isotype control | human IgG2 | IgG2, λ | IP0070 | |||
| BE0302-25MG | InVivoMAb anti-mouse CD20 | AISB12 | IgG2a, κ | Flow cytometry, Western blot, Not recommended for in vivo B cell depletion | BE0089 | IP0070 | |
| BE0303-1MG | InVivoMAb anti-mouse IL-17F | MM17F8F5.1A9 | IgG1, κ | in vivo IL-17F neutralization | BE0083 | IP0070 | |
| BE0304-1MG | InVivoMAb anti-mouse BTLA (CD272) | 6F7 | IgG1, κ | in vivo BTLA+ B cell and CD4 T cell depletion*, Flow cytometry, *see description for details | BE0083 | IP0070 | |
| BE0305-1MG | InVivoMAb anti-mouse CLEC9A (CD370) | 7H11 | IgG1, κ | in vivo CLEC9A blockade, in vivo Ag targeting to CLEC9A+ DCs, Western blot, ELISA, Immunoprecipitation, Immunofluorescence, Flow cytometry | BE0088 | IP0070 | |
| BE0306-1MG | InVivoMAb anti-human/monkey MHC class II (HLA-DR) | L243 | IgG2a, κ | in vitro blocking of MHC class II HLA-DR, HLA class II binding assay, in vitro MHC class II HLA-DR expressing cell negative selection, Western blot, Flow cytometry | BE0085 | IP0070 | |
| BE0307-1MG | InVivoMAb anti-mouse CD16/CD32 | 2.4G2 | IgG2b, κ | in vitro Fc receptor blocking, in vivo Fc receptor blocking | BE0090 | IP0080 | |
| BE0308-1MG | InVivoMAb anti-rat CD4 | OX-38 | IgG2a, κ | in vivo CD4+ T cell depletion, Flow cytometry | BE0085 | IP0070 | |
| BE0309-1MG | InVivoMAb anti-mouse CXCL9 (MIG) | MIG-2F5.5 | IgG, κ | in vivo CXCL9 neutralization, Immunofluorescence | BE0091 | IP0070 | |
| BE0310-1MG | InVivoMAb anti-mouse VISTA | 13F3 | IgG | in vivo blocking of VISTA signaling, in vitro blocking of VISTA signaling | BE0091 | IP0070 | |
| BE0311-1MG | InVivoMAb anti-mouse CD317 (BST2, PDCA-1) | 927 | IgG2b, κ | in vivo pDC depletion, Immunofluorescence, Flow cytometry | BE0090 | IP0070 | |
| BE0312-1MG | InVivoMAb anti-mouse IFNγ | H22 | IgG | in vivo IFNγ neutralization, in vitro IFNγ neutralization | BE0091 | IP0070 | |
| BE0313-10MG | InVivoMAb anti-mouse IL-23 (p19) | G23-8 | IgG1, κ | in vivo IL-23p19 neutralization, Western blot | BE0088 | IP0070 | |
| BE0314-1MG | InVivoMAb anti-mouse TIM-1 (CD365) | 3D10 | IgG1, κ | in vivo TIM-1 blockade, in vitro TIM-1 blockade | BE0088 | IP0070 | |
| BE0315-10MG | InVivoMAb anti-mouse IL-15 | AIO.3 | IgG2a, λ | in vivo IL-15 neutralization, in vitro IL-15 neutralization | BE0089 | IP0070 | |
| BE0316-1MG | InVivoMAb anti-mouse CCR3 (CD193) | 6S2-19-4 | IgG2b, λ | in vivo eosinophil depletion | BE0090 | IP0070 | |
| BE0317-1MG | InVivoMAb anti-mouse CD38 | NIMR5 | IgG2a, κ | in vivo CD38 stimulation, in vitro CD38 stimulation, in vitro B cell activation, Immunofluorescence, ELISA, Flow cytometry | BE0089 | IP0070 | |
| BE0318-1MG | InVivoMAb anti-human Ganglioside GD2 | 14G2a | IgG2a, κ | in vitro induction of apoptosis in GD2+ cells, in vivo inhibition of GD2+ tumor cell growth | BE0085 | IP0070 | |
| BE0319-1MG | InVivoMAb anti-mouse FasL (CD178) | MFL3 | IgG | in vivo FasL blockade, In vitro FasL blockade, Functional assay, Immunohistochemistry (paraffin), Flow Cytometry | BE0091 | IP0070 | |
| BE0320-1MG | InVivoMAb anti-mouse Ly6G/Ly6C | NIMP-R14 | IgG2b, κ | in vivo neutrophil depletion, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry | BE0090 | IP0070 | |
| BE0321-1MG | InVivoMAb anti-mouse NKG2A/C/E | 20D5 | IgG2a, κ | in vivo NKG2A blockade (see description), in vitro NKG2A blockade, Immunohistochemistry (frozen), Flow cytometry | BE0089 | IP0070 | |
| BE0322-1MG | InVivoMAb anti-mouse CD172a (SIRPα) | P84 | IgG1, κ | in vivo SIRPα blocking, In vitro SIRPα blocking, Western blot, Immunoprecipitation, Flow cytometry | BE0088 | IP0070 | |
| BE0323-1MG | InVivoMAb anti-mouse TL1A (TNFSF15) | 5G4.6 | IgG | in vivo TL1A neutralization, Flow cytometry | BE0091 | IP0070 | |
| BE0324-1MG | InVivoMAb anti-human/mouse denatured collagen type-I (RGD motif) | XL313 | IgG1, κ | Western blot, Immunofluorescence, in vivo administration (see description) | |||
| BE0325-1MG | InVivoMAb anti-West Nile/dengue virus E protein | E60 | IgG2a, κ | Neutralization of WNV, Neutralization of DENV1,2,3,4 | BE0085 | IP0070 | |
| BE0326-1MG | InVivoMAb anti-mouse IL-27 p28 | MM27.7B1 | IgG2a, κ | in vivo IL-27 p28 neutralization, in vitro IL-27 p28 neutralization, Flow cytometry | BE0085 | IP0070 | |
| BE0327-1MG | InVivoMAb anti-human IL-9 | MH9A4 | IgG2b, κ | Flow cytometry, ELISA | BE0086 | IP0070 | |
| BE0328-1MG | InVivoMAb anti-mouse CD28 | D665 | IgG1, κ | in vivo T cell stimulation/activation, in vitro T cell stimulation/activation | BE0083 | IP0070 | |
| BE0329-1MG | InVivoMAb anti-mouse CD71 (TfR1) | 8D3 | IgG2a | in vivo depletion of CD71+ cells, Immunofluorescence, Immunohistochemistry (frozen), Western blot | BE0089 | IP0070 | |
| BE0330-1MG | InVivoMAb anti-mouse CD69 | CD69.2.2 | IgG1, κ | in vivo down-regulation of CD69 expression, Functional assays | BE0083 | IP0070 | |
| BE0331-1MG | InVivoMAb anti-rat/mouse CD71 (TfR1) | OX-26 | IgG2a, κ | Targeted drug delivery to the brain, Immunohistochemistry (frozen), Flow cytometry | BE0085 | IP0070 | |
| BE0332-1MG | InVivoMAb anti-mouse FGL-1 | 177R4 | IgG2a, κ | in vivo FGL-1 blockade, in vitro FGL-1 blockade, Flow cytometry, Immunohistochemistry (paraffin) | BE0089 | IP0070 | |
| BE0333-1MG | InVivoMAb anti-mouse/human/rat LRP1 (CD91) | 11H4 | IgG1, κ | Western blot, Immunofluorescence, Immunoprecipitation | BE0083 | IP0070 | |
| BE0334-1MG | InVivoMAb anti-mouse NKG2D (CD314) | CX5 | IgG1, κ | in vivo NKG2D blockade, in vitro NKG2D blockade, Flow Cytometry | BE0088 | IP0070 | |
| BE0335-1MG | InVivoMAb anti-human MAGE-C2 (CT10) | LX-CT10.5 | IgG2a, κ | Immunohistochemistry (paraffin), Immunofluorescence, Western blot | BE0085 | IP0070 | |
| BE0336-1MG | InVivoMAb anti-human MUC1 (CD227) | C595 (NCRC48) | IgG3, κ | in vivo administration in mouse xenograft models, Immunohistochemistry (paraffin), Immunofluorescence, in vitro cell cytotoxicity assay, Western blot | BE0093 | IP0070 | |
| BE0337-1MG | InVivoMAb anti-mouse CD96 | 3.3 | IgG1, λ | in vivo CD96 blocking, in vitro CD96 blocking, Flow cytometry | BE0088 | IP0070 | |
| BE0338-1MG | InVivoMAb anti-human CD220 (Insulin Receptor) | IR 83-22 | IgG1 | Western blot | BE0083 | IP0070 | |
| BE0339-1MG | InVivoMAb anti-mouse NKG2AB6 | 16A11 | IgG2b, κ | Flow cytometry | BE0086 | IP0070 | |
| BE0340-1MG | InVivoMAb anti-human/monkey MDR-1 (CD243) | UIC2 | IgG2a, κ | in vivo MDR-1 blocking/depletion in xenogeneic murine, tumor models, in vitro MDR-1 blocking, Immunohistochemistry (paraffin) | BE0085 | IP0070 | |
| BE0341-1MG | InVivoMAb anti-human EphA2 | B2D6 | IgG2b, κ | Immunohistochemistry (paraffin), Immunoprecipitation, Functional assay | BE0086 | IP0070 | |
| BE0342-1MG | InVivoMAb recombinant Flt-3L-Ig (hum/hum) | Flt-3L Fc-G1 | IP0070 | ||||
| BE0343-1MG | InVivoMAb anti-human CD71 (TfR) | 5E9C11 | IgG1, κ | Western blot, Immunoprecipitation, Flow cytometry | BE0083 | IP0070 | |
| BE0344-1MG | InVivoMAb anti-mouse TIM-4 | F31-5G3 | IgG1, κ | Flow cytometry | BE0088 | IP0070 | |
| BE0345-1MG | InVivoMAb anti-mouse/rat/bovine VLDL-R | IgG-6A6 | IgG1, λ | Western blot | BE0083 | IP0070 | |
| BE0346-1MG | InVivoMAb anti-mouse CD326 (EpCAM) | G8.8 | IgG2a, κ | Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry, Western blot | BE0089 | IP0070 | |
| BE0347-1MG | InVivoMAb anti-human CSF1R (CD115) | 2-4A5-4 | IgG1, κ | in vitro CSF1R neutralization, Immunohistochemistry (paraffin), Functional assays, Flow cytometry | IP0070 | ||
| BE0348-1MG | InVivoMAb anti-mouse CD27 | RM27-3E5 | IgG2a, κ | in vivo CD27 stimulation, in vitro CD27 stimulation, Immunoprecipitation, Flow cytometry | BE0089 | IP0070 | |
| BE0350-1MG | InVivoMAb anti-mouse/human PrP (prion protein) | TW1 | IgG2a | in vivo PrP blocking, Western blot | BE0085 | IP0070 | |
| BE0351-1MG | InVivoMAb anti-human NKG2D (CD314) | 1D11 | IgG1, κ | in vitro NKG2D blocking, Immunoprecipitation, Flow cytometry | BE0083 | IP0070 | |
| BE0352-1MG | InVivoMAb anti-mouse E-Cadherin (CD324) | DECMA-1 | IgG1, κ | in vivo E-Cadherin neutralization, In vitro E-Cadherin neutralization, Immunofluorescence, Immunoprecipitation, Western blot | BE0088 | IP0070 | |
| BE0353-1MG | InVivoMAb anti-mouse/human/rat/monkey ICOS (CD278) | C398.4A | IgG | in vitro T cell stimulation/activation, Flow cytometry, Immunoprecipitation | BE0091 | IP0070 | |
| BE0354-1MG | InVivoMAb anti-human CD2 | CB.219 | IgG2b, κ | in vivo CD2 blockade in huCD2tg mice | BE0086 | IP0070 | |
| BE0355-1MG | InVivoMAb anti-human CA19-9 | 1116-NS-19-9 | IgG1, κ | Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry | BE0083 | IP0070 | |
| BE0356-1MG | InVivoMAb anti-mouse CD20 | MB20-11 | IgG2c, κ | in vivo B cell depletion, Western blot | BE0366 | IP0070 | |
| BE0357-1MG | InVivoMAb anti-SARS-CoV-2 S protein (RBD epitope A) | SARS2-01 | IgG1, κ | in vitro blocking of SARS-CoV-2 S protein, Flow cytometry, ELISA | BE0083 | IP0070 | |
| BE0358-1MG | InVivoMAb anti-SARS-CoV-2 S protein (NTD) | SARS2-29 | IgG1, κ | Flow cytometry, ELISA | BE0083 | IP0070 | |
| BE0359-1MG | InVivoMAb anti-SARS-CoV-2 S protein (RBD epitope B) | SARS2-34 | IgG1, κ | in vitro blocking of SARS-CoV-2 S protein, Flow cytometry, ELISA | BE0083 | IP0070 | |
| BE0360-1MG | InVivoMAb anti-mouse CD24 | M1/69 | IgG2b, κ | in vivo administration, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry | BE0090 | IP0070 | |
| BE0361-1MG | InVivoMAb anti-mouse PD-L1 (B7-H1) | 10F.2H11 | IgG2b, κ | in vivo blocking of PD-L1/CD80 (B7-1) interactions, in vitro blocking of PD-L1/CD80 (B7-1) interactions, ELISA, Flow cytometry | BE0090 | IP0070 | |
| BE0362-1MG | InVivoMAb anti-human CEACAM 1/3/5/6/8 | 6G5j | IgG1, κ | Western blot, ELISA, Immunofluorescence, Immunohistochemistry (paraffin), Flow cytometry | BE0083 | IP0070 | |
| BE0363-1MG | InVivoMAb anti-human CEACAM7 | P3-7B | IgG1, κ | Western blot*, ELISA*, Immunoprecipitation*, Immunohistochemistry*, Flow cytometry*, *Based on unpublished data | BE0083 | IP0070 | |
| BE0364-1MG | InVivoMAb anti-mouse BTLA (CD272) | HMBT-6B2 | IgG | in vivo BTLA blockade, Flow cytometry | BE0091 | IP0070 | |
| BE0365-1MG | InVivoMAb anti-mouse CD80 (B7-1) | RM80 | IgG2a | in vivo CD80 blockade, in vitro CD80 blockade, Flow cytometry | BE0089 | IP0070 | |
| BE0366-1MG | InVivoMAb mouse IgG2c isotype control, anti-dengue virus | DV5-1 | IgG2c, κ | IP0070 | |||
| BE0367-1MG | InVivoMAb anti-human CD71 (TfR1) | B3/25 | IgG1, κ | in vitro CD71 targeting, in vivo CD71 targeting, Immunofluorescence | BE0083 | IP0070 | |
| BE0368-1MG | InVivoMAb anti-human/mouse/rat amyloid-beta | MOAB-2 | IgG2b, λ | Western blot, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, ELISA | BE0086 | IP0070 | |
| BE0370-1MG | InVivoMAb anti-human CD71 (TfR1) | T56/14 | IgG1, κ | Flow cytometry, Immunoprecipitation | BE0083 | IP0070 | |
| BE0371-1MG | InVivoMAb anti-mouse IL-12 p35 | C18.2 | IgG2a, κ | in vivo IL-12 p35 neutralization, in vitro IL-12 p35 neutralization, ELISA, Immunoprecipitation | BE0089 | IP0070 | |
| BE0372-1MG | InVivoMAb anti-mouse osteopontin (SPP1) | 100D3 | IgG2c, κ | in vivo OPN neutralization, in vitro OPN neutralization, ELISA | BE0366 | IP0070 | |
| BE0374-1MG | InVivoMAb anti-mouse FAP | 73.3 | IgG1, κ | Chimeric antigen receptor construction, Flow cytometry | BE0083 | IP0070 | |
| BE0375-1MG | InVivoMAb anti-human EGFR | 425 | IgG2a, κ | in vivo EGFR blockade in xenografts, in vitro EGFR blockade, Immunoprecipitation | BE0085 | IP0070 | |
| BE0376-1MG | InVivoMAb anti-human CD71 (TfR1) | 2C1 | IgG2b, κ | Flow cytometry*, Immunoprecipitation*, Western blot*, *Based on unpublished data | BE0086 | IP0070 | |
| BE0377-1MG | InVivoMAb anti-mouse CD31 (PECAM-1) | 390 | IgG2a, κ | in vivo CD31 blocking, Intravital imaging, Immunofluorescence, Flow cytometry | BE0089 | IP0070 | |
| BE0378-1MG | InVivoMAb anti-mouse CD16.2 (FcγRIV) | 9E9 | IgG | in vivo CD16.2 blockade, in vitro CD16.2 blockade, Flow cytometry | BE0091 | IP0070 | |
| BE0379-1MG | InVivoMAb anti-mouse TSLP | 28F12 | IgG2a, κ | in vivo TSLP neutralization, in vitro TSLP neutralization | BE0089 | IP0070 | |
| BE0380-1MG | InVivoMAb anti-human c-Kit (CD117) | SR-1 | IgG2a, κ | in vivo c-Kit+ cell depletion, in vitro c-Kit targeting, Immunohistochemistry (frozen) | BE0085 | IP0070 | |
| BE0381-1MG | InVivoMAb anti-human GM-CSF | BVD2-21C11 | IgG2a, κ | Immunofluorescence, ELISA, Flow cytometry | BE0089 | IP0070 | |
| BE0382-1MG | InVivoMAb anti-mouse/human/rat osteopontin (SPP1) | MPIIIB10 | IgG1, κ | in vivo OPN neutralization, in vitro OPN neutralization, Immunohistochemistry (paraffin), Western blot | BE0083 | IP0070 | |
| BE0383-1MG | InVivoMAb anti-mouse/human/rat PD-L1 | 368A.4H1 | Mouse IgG1, κ | in vivo PD-L1 blockade , in vitro PD-L1 blockade , Flow cytometry | BE0083 | IP0070 | |
| BE0384-1MG | InVivoMAb anti-human GM-CSF | BVD2-23B6 | IgG2a, κ | in vitro GM-CSF neutralization, ELISA | BE0089 | IP0070 | |
| BE0385-1MG | InVivoMAb anti-mouse DKK3 | DKK3-4.22 | IgG1, κ | in vivo DKK3 blocking, in vitro DKK3 blocking, Western blot, Flow cytometry, | BE0083 | IP0070 | |
| BE0386-1MG | InVivoMAb anti-human CD326 (EpCAM) | Ber-EP4 | IgG1, κ | Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry, Immunoprecipitation | BE0083 | IP0070 | |
| BE0387-1MG | InVivoMAb anti-mouse/human phosphorylated PD-1 (CD279) | 407.6G12 | IgG2a, κ | Western Blot, Flow Cytometry | BE0085 | IP0070 | |
| BE0388-1MG | InVivoMAb anti-human CD71 (TfR1) | BK19.9 | IgG1, κ | Immunohistochemistry (frozen) | BE0083 | IP0070 | |
| BE0389-1MG | InVivoMAb anti-canine CD34 | 1H6 | IgG1, κ | Immunohistochemistry (frozen), Flow cytometry, Western blot, | BE0083 | IP0070 | |
| BE0391-1MG | InVivoMAb anti-human MUC16 | VK8 | Mouse IgG1, κ | Flow cytometry, Western blot | BE0083 | IP0070 | |
| BE0392-1MG | InVivoMAb anti-mouse myeloperoxidase (MPO) | 6G4 | IgG2c, κ | in vivo administration, in vitro administration, Immunofluorescence, , | BE0366 | IP0070 | |
| BE0394-1MG | InVivoMAb anti-mouse IL-25 | 2C3 | IgG1, κ | in vivo IL-25 neutralization | BE0083 | IP0070 | |
| BE0395-1MG | InVivoMAb anti-mouse/human Mac-2 (Galectin-3) | M3/38 (TIB-166) | IgG2a, κ | Western blot, Immunofluorescence, Immunohistochemistry (paraffin), Immunoprecipitation, | BE0089 | IP0070 | |
| BE0396-1MG | InVivoMAb anti-human/mouse GRP78 | C38 | IgG2b, κ | in vivo GRP78 blockade, in vitro GRP78 blockade, Western blot, Flow cytometry, , | BE0086 | IP0070 | |
| BE0398-1MG | InVivoMAb anti-mouse CD83 | Michel-17 | IgG1, κ | in vivo CD83 engagement, in vitro CD83 blockade, Flow cytometry, ELISA, | BE0088 | IP0070 | |
| BE0399-1MG | InVivoMAb anti-mouse VEGF-A | 2G11-2A05 | IgG2a, κ | in vivo VEGF-A neutralization, Western blot, | BE0089 | IP0070 | |
| BE0400-1MG | InVivoMAb anti-mouse RGMb | 307.9D1 | IgG2a, κ | in vivo RGMb blockade, ELISA, Flow cytometry, , | BE0089 | IPT060 | |
| BE0401-1MG | InVivoMAb anti-human CEACAM5 | 4H11-8 | IgG1, κ | , , | BE0083 | IP0070 | |
| BE0402-1MG | InVivoMAb anti-human GPC-2 | CT3 | IgG1, κ | , , | BE0083 | IP0070 | |
| BE0403-1MG | InVivoMAb anti-mouse CD96 | 6A6/CD96 | IgG2a, λ | BE0089 | IP0070 | ||
| BE0404-1MG | InVivoMAb anti-human GPC3 | YP7 | IgG1, κ | , , | BE0083 | IP0070 | |
| BE0406-1MG | InVivoMAb anti-human CD2 | LO-CD2a | IgG2b, κ | , , | BE0090 | IP0070 | |
| BE0407-1MG | InVivoMAb anti-human Fy3 | MIMA-29 | IgG2a, κ | , , | BE0085 | IP0070 | |
| BE0408-1MG | InVivoMAb anti-human TROP-2 | Pr1E11 | IgG1, κ | Western blot, Immunohistochemistry (frozen), Flow cytometry, , | BE0083 | IP0070 | |
| BE0409-1MG | InVivoMAb anti-human BRCA1 | BR64 | IgG1, κ | , , | BE0083 | IP0070 | |
| BE0410-1MG | InVivoMAb anti-human EphA2 | SHM16 | IgG1, κ | BE0083 | IP0070 | ||
| BE0411-1MG | InVivoMAb anti-human GC1q R (C1QBP) | 60.11 | IgG1, κ | , , | BE0083 | IP0070 | |
| BE0412-1MG | InVivoMAb anti-human GPC3 | HS20 | IgG1, κ | , , | CP174 | IP0070 | |
| BE0413-1MG | InVivoMAb anti-rat TCR α/β | R73 | IgG1, κ | in vivo administration | BE0083 | IP0070 | |
| BE0414-1MG | InVivoMAb anti-rat TCR γ/δ | V65 | IgG1, κ | in vivo γ/δ T cell depletion, Flow cytometry | BE0083 | IP0070 | |
| BE0415-1MG | InVivoMAb anti-rat CD8α | OX-8 | IgG1, κ | in vivo CD8+ T cell depletion, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | BE0083 | IP0070 | |
| BE0416-1MG | InVivoMAb anti-human/mouse GRP78 | N88 | IgG1, κ | in vivo administration, Functional assays | BE0083 | IP0070 | |
| BE0417-1MG | InVivoMAb anti-rat CD2 | OX-34 | IgG2a, κ | in vivo CD2 blockade, in vitro CD2 blockade, Western blot | BE0085 | IP0070 | |
| New (1/3/2024) | BE0418-1MG | InVivoMAb anti-rat CD28 | JJ316 | IgG1, κ | in vivo T cell stimulation/activation | BE0083 | IP0070 |
| New (1/18/2024) | BE0419-1MG | InVivoMAb anti-rat IL-4 | OX-81 | IgG1, κ | in vivo IL-4 neutralization, ELISA, Flow cytometry | BE0083 | IP0070 |
| New (2/2/2024) | BE0420-1MG | InVivoMAb anti-mouse CD205 (DEC-205) | NLDC-145 | IgG2a, κ | in vivo antigen-targeting to DEC-205, in vitro antigen-targeting to DEC-205, Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry, | BE0089 | IP0070 |
| New (2/26/2024) | BE0421-1MG | InVivoMAb anti-chikungunya virus E2 | CHK-265 | IgG2c, λ | Viral entry and egress inhibition | BE0366 | IP0070 |
| New (3/5/2024) | BE0422-1MG | InVivoMAb anti-mouse CD86 (B7-2) | 2D10 | IgG2b, κ | Immunoprecipitation, Flow cytometry, Functional assays, | BE0090 | IP0070 |
| BP0001-1-5MG | InVivoPlus anti-mouse CD3ε | 145-2C11 | IgG1 | in vivo T cell depletion, in vitro T cell stimulation/activation, Immunofluorescence, Flow cytometry, Western blot | BP0091 | IP0070 | |
| BP0003-1-5MG | InVivoPlus anti-mouse CD4 | GK1.5 | IgG2b, κ | in vivo CD4+ T cell depletion, Flow cytometry, Western blot | BP0090 | IP0065 | |
| BP0004-1-5MG | InVivoPlus anti-mouse CD8α | 53-6.7 | IgG2a, κ | in vivo CD8+ T cell depletion, Immunofluorescence, Flow cytometry, Western blot | BP0089 | IP0065 | |
| BP0012-5MG | InVivoPlus anti-mouse CD25 (IL-2Rα) | PC-61.5.3 | IgG1, λ | in vivo regulatory T cell depletion, Flow cytometry | BP0088 | IP0070 | |
| BP0016-2-5MG | InVivoPlus anti-mouse CD40 | FGK4.5/FGK45 | IgG2a | in vivo CD40 activation, in vitro B cell stimulation/activation | BP0089 | IP0070 | |
| BP0017-1-5MG | InVivoPlus anti-mouse CD40L (CD154) | MR-1 | IgG | in vivo blocking of CD40/CD40L signaling, in vitro blocking of CD40/CD40L signaling, Western blot | BP0091 | IP0070 | |
| BP0031-5MG | InVivoPlus anti-mouse OX40 (CD134) | OX-86 | IgG1, κ | in vivo OX40 activation, in vitro OX40 activation, Western blot | BP0088 | IP0070 | |
| BP0032-5MG | InVivoPlus anti-mouse CTLA-4 (CD152) | UC10-4F10-11 | IgG | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blot | BP0091 | IP0065 | |
| BP0033-2-5MG | InVivoPlus anti-mouse PD-1 (CD279) | J43 | IgG | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Western blot | BP0091 | IP0065 | |
| BP0036-5MG | InVivoPlus anti-mouse NK1.1 | PK136 | IgG2a, κ | in vivo NK cell depletion, Flow cytometry | BP0085 | IP0070 | |
| BP0045-5MG | InVivoPlus anti-mouse IL-4 | 11B11 | IgG1, κ | in vivo IL-4 neutralization, in vitro IL-4 neutralization, in vivo IL-4 receptor stimulation (as a complex with IL-4), Flow cytometry, Western blot | BP0088 | IP0070 | |
| BP0050-5MG | InVivoPlus anti-mouse IL-10R (CD210) | 1B1.3A | IgG1, κ | in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, Flow cytometry, Western Blot | BP0088 | IPT065 | |
| BP0051-5MG | InVivoPlus anti-mouse IL-12 p40 | C17.8 | IgG2a, κ | in vivo IL-12p40 neutralization, p40 affinity chromatography, Immunoprecipitation, ELISA, Flow cytometry, Western blot | BP0089 | IP0070 | |
| BP0055-5MG | InVivoPlus anti-mouse IFNγ | XMG1.2 | IgG1, κ | in vivo IFNγ neutralization, in vitro IFNγ neutralization, ELISPOT, Flow cytometry, Western blot | BP0088 | IPT080 | |
| BP0057-5MG | InVivoPlus anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-β | 1D11.16.8 | IgG1, κ | in vivo TGFβ neutralization, in vitro TGFβ neutralization, Western blot | BP0083 | IP0070 | |
| BP0058-5MG | InVivoPlus anti-mouse TNFα | XT3.11 | IgG1 | in vivo TNFα neutralization, in vitro TNFα neutralization, Western blot | BP0088 | IP0080 | |
| BP0060-5MG | InVivoPlus anti-mouse VEGFR-2 | DC101 | IgG1, κ | in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling, Western blot | BP0088 | IP0070 | |
| BP0061-5MG | InVivoPlus anti-mouse CD8α | 2.43 | IgG2b, κ | in vivo CD8+ T cell depletion, Western blot | BP0090 | IP0070 | |
| BP0063-5MG | InVivoPlus anti-mouse GITR | DTA-1 | IgG2b, λ | in vivo GITR stimulation | BP0090 | IP0070 | |
| BP0066-5MG | InVivoPlus anti-mouse Thy1.2 (CD90.2) | 30H12 | IgG2b, κ | in vivo ILC depletion, in vivo T cell depletion, Western blot | BP0090 | IP0070 | |
| BP0075-5MG | InVivoPlus anti-mouse Ly6G/Ly6C (Gr-1) | RB6-8C5 | IgG2b, κ | in vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | BP0090 | IP0070 | |
| BP0075-1-5MG | InVivoPlus anti-mouse Ly6G | 1A8 | IgG2a, κ | in vivo neutrophil depletion, in vivo MDSC depletion, Immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry | BP0089 | IP0070 | |
| BP0079-5MG | InVivoPlus anti-human MHC Class I (HLA-A, HLA-B, HLA-C) | W6/32 | IgG2a, κ | Functional assays | BP0085 | IP0065 | |
| BP0083-5MG | InVivoPlus mouse IgG1 isotype control, unknown specificity | MOPC-21 | IgG1, κ | IP0065 | |||
| BP0085-5MG | InVivoPlus mouse IgG2a isotype control, unknown specificity | C1.18.4 | IgG2a, κ | IP0070 | |||
| BP0086-5MG | InVivoPlus mouse IgG2b isotype control, unknown specificity | MPC-11 | IgG2b, κ | IP0070 | |||
| BP0087-5MG | InVivoPlus polyclonal Syrian hamster IgG | polyclonal Syrian hamster IgG | IgG | IP0070 | |||
| BP0088-5MG | InVivoPlus rat IgG1 isotype control, anti-horseradish peroxidase | HRPN-CP167 | IgG1, κ | IP0070 | |||
| BP0089-5MG | InVivoPlus rat IgG2a isotype control, anti-trinitrophenol | 2A3 | IgG2a, κ | IP0065 | |||
| BP0090-5MG | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin | LTF-2-CP166 | IgG2b, κ | IP0070 | |||
| BP0091-5MG | InVivoPlus polyclonal Armenian hamster IgG | polyclonal Armenian hamster IgG | IgG | IP0070 | |||
| BP0099-5MG | InVivoPlus recombinant CTLA-4-Ig (hum/hum) | CTLA-4-Ig (hum/hum) | IP0070 | ||||
| BP0101-5MG | InVivoPlus anti-mouse PD-L1 (B7-H1) | 10F.9G2™ | IgG2b, κ | in vivo PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry, Western blot | BP0090 | IP0065 | |
| BP0115-5MG | InVivoPlus anti-mouse TIM-3 (CD366) | RMT3-23 | IgG2a, κ | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometry | BP0089 | IP0070 | |
| BP0117-5MG | InVivoPlus anti-mouse CD8α | YTS 169.4 | IgG2b, κ | in vivo CD8+ T cell depletion, Western blot | BP0090 | IP0070 | |
| BP0131-5MG | InVivoPlus anti-mouse CTLA-4 (CD152) | 9H10 | IgG | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Western blot | BP0087 | IP0070 | |
| BP0146-5MG | InVivoPlus anti-mouse PD-1 (CD279) | RMP1-14 | IgG2a, κ | in vivo blocking of PD-1/PD-L signaling | BP0089 | IP0070 | |
| BP0164-5MG | InVivoPlus anti-mouse CTLA-4 (CD152) | 9D9 | IgG2b | in vivo CTLA-4 neutralization, Western blot | BP0086 | IP0070 | |
| BP0169-5MG | InVivoPlus anti-mouse 4-1BB (CD137) | LOB12.3 | IgG1, κ | in vivo activation of 4-1BB | BP0088 | IP0080 | |
| BP0173-5MG | InVivoPlus anti-mouse IL-17A | 17F3 | IgG1, κ | in vivo IL-17A neutralization | BP0083 | IP0070 | |
| BP0174-5MG | InVivoPlus anti-mouse LAG-3 | C9B7W | IgG1, κ | in vivo LAG-3 neutralization, in vitro LAG-3 neutralization, Flow cytometry, Western blot | BP0088 | IP0070 | |
| BP0175-5MG | InVivoPlus anti-mouse CD71 (TfR1) | R17 217.1.3/TIB-219 | IgG2a, κ | in vivo depletion of CD71+ cells | BP0089 | IP0070 | |
| BP0213-5MG | InVivoPlus anti-mouse CSF1R (CD115) | AFS98 | IgG2a, κ | in vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, Flow cytometry, Western blot | BP0089 | IP0070 | |
| BP0239-5MG | InVivoPlus anti-mouse 4-1BB (CD137) | 3H3 | IgG2a | in vivo 4-1BB stimulation, in vitro 4-1BB stimulation | BP0089 | IP0070 | |
| BP0241-5MG | InVivoPlus anti-mouse IFNAR-1 | MAR1-5A3 | IgG1, κ | in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade, Western blot | BP0083 | IP0070 | |
| BP0273-5MG | InVivoPlus anti-mouse PD-1 (CD279) | 29F.1A12™ | IgG2a | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Immunohistochemistry (frozen), Immunofluorescence, Western blot, Flow cytometry | BP0089 | IP0070 | |
| BP0274-5MG | InVivoPlus anti-mouse TIGIT | 1G9 | IgG1, κ | in vivo TIGIT stimulation, Flow cytometry | BP0083 | IP0070 | |
| BP0283-5MG | InVivoPlus anti-mouse/human/rat CD47 (IAP) | MIAP410 | IgG1, κ | in vivo CD47 blockade, in vitro CD47 blocking, Immunofluorescence | BP0083 | IP0070 | |
| BP0290-5MG | InVivoPlus rat IgG1 isotype control, anti-trinitrophenol | TNP6A7 | IgG1, λ | IP0070 | |||
| BP0297-5MG | InVivoPlus human IgG1 isotype control | human IgG1 | IgG1, κ | IP0070 | |||
| BP0301-5MG | InVivoPlus human IgG2 isotype control | human IgG2 | IgG2, λ | IP0070 | |||
| BP0307-5MG | InVivoPlus anti-mouse CD16/CD32 | 2.4G2 | IgG2b, κ | in vitro Fc receptor blocking, in vivo Fc receptor blocking | BP0090 | IP0080 | |
| BP0308-5MG | InVivoPlus anti-rat CD4 | OX-38 | IgG2a, κ | in vivo CD4+ T cell depletion, Flow cytometry | BP0085 | IP0070 | |
| BP0310-5MG | InVivoPlus anti-mouse VISTA | 13F3 | IgG | in vivo blocking of VISTA signaling, in vitro blocking of VISTA signaling | BP0091 | IP0070 | |
| BP0329-5MG | InVivoPlus anti-mouse CD71 (TfR1) | 8D3 | IgG2a | in vivo depletion of CD71+ cells, Immunofluorescence, Immunohistochemistry (frozen), Western blot | BP0089 | IP0070 | |
| BP0356-5MG | InVivoPlus anti-mouse CD20 | MB20-11 | IgG2c, κ | in vivo B cell depletion, Western blot | BE0366 | IP0070 | |
| BP0366-5MG | InVivoPlus mouse IgG2c isotype control, anti-dengue virus | DV5-1 | IgG2c, κ | IP0070 | |||
| CP001-1MG | RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) | 10F.9G2™-CP001 | IgG1, κ | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2b 10F.9G2 antibody | CP047 | IP0070 | |
| CP002-1MG | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | RMP1-14-CP002 | IgG1, κ | in vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibody | CP047 | IP0070 | |
| CP004-1MG | RecombiMAb anti-mouse PD-1 (CD279) | 29F.1A12™-CP004 | IgG1, κ | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry*, *Reported for the original rat IgG2a 29F.1A12 antibody, | BP0083 | IP0070 | |
| CP005-1MG | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | 29F.1A12™-CP005 | IgG1, κ | in vivo blocking of PD-1/PD-L signaling* , in vitro PD-1 neutralization* , Immunohistochemistry (frozen)* , Immunofluorescence* , Western blot* , Flow cytometry* , *Reported for the original rat IgG2a 29F.1A12 antibody , | CP047 | IP0070 | |
| CP006-1MG | RecombiMAb anti-mouse CTLA-4 (CD152) | 9D9-CP006 | IgG1, κ | in vivo CTLA-4 neutralization*, Western blot*, *Reported for the original mouse IgG2b 9D9 antibody | BP0083 | IP0070 | |
| CP008-1MG | RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG) | 9D9-CP008 | IgG2a, κ | in vivo CTLA-4 neutralization*, Western blot*, *Reported for the original mouse IgG2b 9D9 antibody | CP048 | IP0070 | |
| CP013-1MG | RecombiMAb anti-mouse LAG-3 (D265A) | C9B7W-CP013 | IgG1, κ | in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot*, *Reported for the original rat IgG1 C9B7W antibody | CP047 | IP0070 | |
| CP014-1MG | RecombiMAb anti-mouse LAG-3 | C9B7W-CP014 | IgG2a, κ | in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot*, *Reported for the original rat IgG1 C9B7W antibody | BP0085 | IP0070 | |
| CP017-1MG | RecombiMAb anti-mouse OX40 (CD134) | OX86-CP017 | IgG2a, κ | in vivo OX40 activation*, in vitro OX40 activation*, Western blot*, *Reported for the original rat IgG1 OX-86 antibody | BP0085 | IP0070 | |
| CP018-1MG | RecombiMAb anti-mouse OX40 (CD134) (LALA-PG) | OX86-CP018 | IgG2a, κ | in vivo OX40 activation*, in vitro OX40 activation*, Western blot*, *Reported for the original rat IgG1 OX-86 antibody | CP048 | IP0070 | |
| CP025-1MG | RecombiMAb anti-mouse CD16/CD32 | 2.4G2-CP025 | IgG2a, κ | in vitro Fc receptor blocking*, in vivo Fc receptor blocking*, *Reported for the original rat IgG2b 2.4G2 antibody | BP0085 | IP0070 | |
| CP026-1MG | RecombiMAb anti-mouse CD16/CD32 (LALA-PG) | 2.4G2-CP026 | IgG2a, κ | in vitro Fc receptor blocking*, in vivo Fc receptor blocking*, *Reported for the original rat IgG2b 2.4G2 antibody | CP048 | IP0070 | |
| CP027-1MG | RecombiMAb anti-mouse GITR (D265A) | DTA-1-CP027 | IgG1, κ | in vivo GITR stimulation*, *Reported for the original rat IgG2b DTA-1 antibody | CP047 | IP0070 | |
| CP028-1MG | RecombiMAb anti-mouse GITR | DTA-1-CP028 | IgG2a, κ | in vivo GITR stimulation*, *Reported for the original rat IgG2b DTA-1 antibody | BP0085 | IP0070 | |
| CP029-1MG | RecombiMAb anti-mouse GITR (LALA-PG) | DTA-1-CP029 | IgG2a, κ | in vivo GITR stimulation*, *Reported for the original rat IgG2b DTA-1 antibody | CP048 | IP0070 | |
| CP032-1MG | RecombiMAb anti-mouse CD40L (CD154) (D265A) | MR-1-CP032 | IgG1, κ | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot*, *Reported for the original Armenian hamster IgG MR-1 antibody | CP047 | IP0070 | |
| CP033-1MG | RecombiMAb anti-mouse CD40L (CD154) | MR-1-CP033 | IgG2a, κ | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot*, *Reported for the original Armenian hamster IgG MR-1 antibody | BP0085 | IP0070 | |
| CP034-1MG | RecombiMAb anti-mouse CD40L (CD154) (LALA-PG) | MR-1-CP034 | IgG2a, κ | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot*, *Reported for the original Armenian hamster IgG MR-1 antibody | CP048 | IP0070 | |
| CP038-1MG | RecombiMAb anti-mouse 4-1BB (CD137) (LALA-PG) | LOB12.3-CP038 | IgG2a, κ | in vivo activation of 4-1BB*, *Reported for the original rat IgG1 LOB12.3 antibody | CP048 | IP0070 | |
| CP039-1MG | RecombiMAb anti-mouse 4-1BBL (CD137L) (D265A) | TKS-1-CP039 | IgG1, κ | in vivo 4-1BBL blockade*, ELISA*, *Reported for the original rat IgG2a TKS-1 antibody | CP047 | IP0070 | |
| CP040-1MG | RecombiMAb anti-mouse 4-1BBL (CD137L) | TKS-1-CP040 | IgG2a, κ | in vivo 4-1BBL blockade*, ELISA*, *Reported for the original rat IgG2a TKS-1 antibody | BP0085 | IP0070 | |
| CP041-1MG | RecombiMAb anti-mouse 4-1BBL (CD137L) (LALA-PG) | TKS-1-CP041 | IgG2a, κ | in vivo 4-1BBL blockade*, ELISA*, *Reported for the original rat IgG2a TKS-1 antibody | CP048 | IP0070 | |
| CP042-1MG | RecombiMAb anti-mouse CD28 | D665-CP042 | IgG2a, κ | in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation*, *Reported for the original mouse IgG1 D665 antibody | BP0085 | IP0070 | |
| CP043-1MG | RecombiMAb anti-mouse CD28 (LALA-PG) | D665-CP043 | IgG2a, κ | in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation*, *Reported for the original mouse IgG1 D665 antibody | CP048 | IP0070 | |
| CP044-1MG | RecombiMAb anti-mouse ICOSL (CD275) (D265A) | HK5.3-CP044 | IgG1, κ | in vivo ICOSL neutralization*, *Reported for the original rat IgG2a HK5.3 antibody | CP047 | IP0070 | |
| CP045-1MG | RecombiMAb anti-mouse ICOSL (CD275) | HK5.3-CP045 | IgG2a, κ | in vivo ICOSL neutralization*, *Reported for the original rat IgG2a HK5.3 antibody | BP0085 | IP0070 | |
| CP046-1MG | RecombiMAb anti-mouse ICOSL (CD275) (LALA-PG) | HK5.3-CP046 | IgG2a, κ | in vivo ICOSL neutralization*, *Reported for the original rat IgG2a HK5.3 antibody | CP048 | IP0070 | |
| CP047-1MG | RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme | N/A-CP047 | IgG1, κ | IP0070 | |||
| CP048-1MG | RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme | N/A-CP048 | IgG2a, κ | IP0070 | |||
| CP049-1MG | RecombiMAb mouse IgG2b (LALA-PG) isotype control, anti-hen egg lysozyme | N/A-CP049 | IgG2b, κ | IP0070 | |||
| CP127-1MG | RecombiMAb anti-mouse CD4 | GK1.5-CP127 | IgG2b, κ | in vivo CD4+ T cell depletion* , Flow cytometry* , Western blot* , *Reported for the original rat IgG2b GK1.5 antibody | BP0086 | IP0065 | |
| CP128-1MG | RecombiMAb anti-mouse CD8α | 2.43-CP128 | IgG2b, κ | in vivo CD8+ T cell depletion*, Western blot*, *Reported for the original rat IgG2b 2.43 antibody | BP0086 | IP0070 | |
| CP129-1MG | RecombiMAb anti-mouse Ly6G | 1A8-CP129 | IgG2a, κ | in vivo neutrophil depletion*, in vivo MDSC depletion*, Immunofluorescence*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, Flow cytometry*, *Reported for the original rat IgG2a 1A8 antibody | BP0085 | IP0070 | |
| CP130-1MG | RecombiMAb anti-mouse CD71 (TfR1) | R17 217.1.3-CP130 | IgG2a, κ | in vivo depletion of CD71+ cells*, *Reported for the original rat IgG2a R17 217.1.3 antibody | BP0085 | IP0070 | |
| CP131-1MG | RecombiMAb anti-mouse CSF1R (CD115) | AFS98-CP131 | IgG2a, κ | in vivo macrophage depletion*, in vitro CSF1R neutralization*, in vivo monocyte depletion*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2a AFS98 antibody | BP0085 | IP0070 | |
| CP132-1MG | RecombiMAb anti-mouse VEGFR-2 | DC101-CP132 | IgG2a, κ | in vivo blocking of VEGF/VEGFR-2 signaling*, in vitro blocking of VEGFR signaling*, Western blot*, *Reported for the original rat IgG1 DC101 antibody | BP0085 | IP0070 | |
| CP133-1MG | RecombiMAb anti-mouse CD40 | FGK4.5-CP133 | IgG2a, κ | in vivo CD40 activation*, in vitro B cell stimulation/activation*, *Reported for the original rat IgG2a FGK4.5 antibody | BP0085 | IP0070 | |
| CP134-1MG | RecombiMAb anti-mouse CD8α | YTS 169.4-CP134 | IgG2a, κ | in vivo CD8+ T cell depletion*, Western blot*, *Reported for the original rat IgG2b YTS 169.4 antibody | BP0085 | IP0070 | |
| CP135-1MG | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | RB6-8C5-CP135 | IgG2a, κ | in vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, *Reported for the original rat IgG2b RB6-8C5 antibody | BP0085 | IP0070 | |
| CP146-5MG | RecombiMAb anti-mouse CTLA-4 (CD152) | 9H10-CP146 | IgG1, κ | in vivo CTLA-4 neutralization*, in vitro CTLA-4 neutralization*, Western blot, *Reported for the original Syrian hamster IgG 9H10 antibody | BP0083 | IP0070 | |
| CP147-100MG | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | N/A-CP147 | IgG4, κ | IP0070 | |||
| CP148-1MG | RecombiMAb human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme | N/A-CP148 | IgG4 | IP0070 | |||
| CP149-1MG | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme | N/A-CP149 | IgG1 | IP0070 | |||
| CP150-1MG | RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | N/A-CP150 | IgG2a | IP0070 | |||
| CP151-1MG | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | RMP1-14-CP151 | IgG2a, κ | in vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibody | CP150 | IP0070 | |
| CP152-1MG | RecombiMAb human IgG4 (S228P) isotype control, anti-respiratory syncytial virus | Palivizumab-CP152 | IgG4, κ | IP0070 | |||
| CP153-1MG | RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | RMP1-14-CP153 | IgG2a, κ | in vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibody | CP150 | IP0070 | |
| CP154-1MG | RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG) | 10F.9G2™-CP154 | IgG2a, κ | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2a 10F.9G2™ antibody | CP048 | IP0070 | |
| CP155-1MG | RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | 29F.1A12™-CP155 | IgG2a, κ | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry*, *Reported for the original rat IgG2a 29F.1A12 antibody, | CP156 | IP0070 | |
| CP156-1MG | RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity | MOPC-21-CP156 | IgG2a, κ | IP0070 | |||
| CP157-5MG | RecombiMAb anti-mouse PD-1 (CD279) | RMP1-14-CP157 | IgG2a, κ | in vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibody | BP0085 | IP0070 | |
| CP160-1MG | RecombiMAb mouse IgG2a isotype control, unknown specificity | MOPC-21-CP160 | IgG1, κ | in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot*, *Reported for the original rat IgG1 C9B7W antibody | IP0070 | ||
| CP161-1MG | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus | Palivizumab-CP161 | IgG1 | IP0070 | |||
| CP162-5MG | RecombiMAb anti-mouse PD-1 (CD279) | RMP1-14-CP162 | IgG1, κ | in vivo blocking of PD-1/PD-L signaling*, *Reported for the original rat IgG2a RMP1-14 antibody | BP0083 | IP0070 | |
| CP168-5MG | RecombiMAb anti-mouse PD-L1 (B7-H1) | 10F.9G2™-CP168 | IgG1, κ | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot*, *Reported for the original rat IgG2a RMP1-14 antibody | BP0083 | IP0070 | |
| CP169-1MG | RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus | Palivizumab-CP169 | IgG1, κ | IP0070 | |||
| CP171-1MG | RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme | N/A-CP171 | IgG1, κ | IP0070 | |||
| New (1/19/2024) | CP172-1MG | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | RB6-8C5-CP172 | IgG2b, κ | in vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, *Reported for the original rat IgG2b RB6-8C5 antibody | BP0086 | IP0070 |
| CP173-1MG | RecombiMAb human IgG1 (D265A) isotype control, anti-hen egg lysozyme | N/A-CP173 | IgG1 | IP0070 | |||
| CP174-1MG | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme | N/A-CP174 | IgG1, κ | IP0070 | |||
| New (1/19/2024) | CP175-1MG | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme | N/A-CP175 | IgG1, κ | IP0070 | ||
| IP0065-50ML | InVivoPure pH 6.5 Dilution Buffer | ||||||
| IP0070-50ML | InVivoPure pH 7.0 Dilution Buffer | ||||||
| IP0080-50ML | InVivoPure pH 8.0 Dilution Buffer | ||||||
| IPT060-50ML | InVivoPure pH 6.0T Dilution Buffer | ||||||
| IPT065-50ML | InVivoPure pH 6.5T Dilution Buffer | ||||||
| IPT080-50ML | InVivoPure pH 8.0T Dilution Buffer | ||||||
| RT0263-1MG | ReadyTag anti-c-myc | 9E10 | IgG1 | Western blot, ELISA, Immunoprecipitation, Flow cytometry | IP0070 | ||
| RT0264-1MG | ReadyTag anti-GST | F50-3D12.2 | IgG1 | Western blot | IP0070 | ||
| RT0265-1MG | ReadyTag anti-GFP | F56-6A1.2.3 | IgG2b | Western blot, Immunofluorescence | IP0070 | ||
| RT0266-1MG | ReadyTag anti-6-His | 6-His | IgG1 | Western blot, Immunoprecipitation, Immunofluorescence | IP0070 | ||
| RT0267-1MG | ReadyTag anti-OVA | F2-3.58 | IgG1 | IP0070 | |||
| RT0268-1MG | ReadyTag anti-HA | 12CA5 | IgG2b | ELISA, Western blot, Immunoprecipitation, Immunofluorescence | IP0070 | ||
| RT0269-1MG | ReadyTag anti-DDDDK | AP1501 | IgG2b | Western blot, Immunoprecipitation, Immunofluorescence | IP0070 | ||
| SIM0001-1MG | InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Adalimumab | IgG1 | TNFα neutralization, Flow Cytometry, ELISA, Immunofluoresence, Immunoprecipitation, Immunohistochemistry, Western Blot | CP174 | IP0070 | |
| SIM0002-1MG | InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Cetuximab | IgG1 | EGFR blockade, ELISA, Flow Cytometry | CP174 | IP0070 | |
| SIM0003-1MG | InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Nivolumab | IgG4 | Blocking of PD-1/PD-L signaling, Flow Cytometry, Immunohistochemistry, Western Blot | CP147 | IP0070 | |
| SIM0004-1MG | InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Ipilimumab | IgG1 | CTLA-4 neutralization, Flow Cytometry, ELISA, Western Blot | CP174 | IP0070 | |
| SIM0005-1MG | InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Trastuzumab | IgG1 | Flow Cytometry, ELISA, Immunohistochemistry, Western Blot | CP174 | IP0070 | |
| SIM0006-1MG | InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Infliximab | IgG1 | TNFα neutralization, Flow Cytometry, ELISA, Western Blot | CP174 | IP0070 | |
| SIM0007-1MG | InVivoSIM anti-human VEGF (Bevacizumab Biosimilar) | Bevacizumab | IgG1 | VEGF neutralization , , Flow Cytometry , , ELISA , , Immunoprecipitation , , Western Block | CP174 | IP0070 | |
| SIM0008-1MG | InVivoSIM anti-human CD20 (Rituximab Biosimilar) | Rituximab | IgG1 | Flow Cytometry , , ELISA , , Western Blot | CP174 | IP0070 | |
| SIM0009-1MG | InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Atezolizumab | IgG1 | Flow Cytometry, Western Blot | CP171 | IP0070 | |
| SIM0010-1MG | InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Pembrolizumab | IgG4 | Blocking of PD-1/PD-L signaling, Functional assays | CP147 | IP0070 | |
| SIM0011-1MG | InVivoSIM anti-human C5 (Eculizumab Biosimilar) | Eculizumab | IgG4 | Inhibition of the activation of C5, Functional assays, ELISA, Immunoprecipitation | CP147 | IP0070 | |
| SIM0012-1MG | InVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar) | Ramucirumab | IgG1 | Functional assays, Immunohistochemistry, Flow cytometry | CP174 | IP0070 | |
| SIM0013-1MG | InVivoSIM anti-human IL-17A (Secukinumab Biosimilar) | Secukinumab | IgG1 | Functional assays, ELISA, Immunofluoresence, Immunohistochemistry, Flow Cytometry | CP174 | IP0070 | |
| SIM0014-1MG | InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) | Tocilizumab | IgG1 | Functional assays, ELISA | CP174 | IP0070 | |
| SIM0015-1MG | InVivoSIM anti-human LAG-3 (Relatlimab Biosimilar) | Relatlimab | IgG4, κ | ELISA | CP147 | IP0070 | |
| SIM0016-1MG | InVivoSIM anti-human IgE (Omalizumab Biosimilar) | Omalizumab | IgG1, κ | IgE neutralization , , Flow cytometry , , ELISA | CP174 | IP0070 | |
| SIM0017-1MG | InVivoSIM anti-human NGF (Tanezumab Biosimilar) | Tanezumab | IgG2, κ | NGF neutralization , , ELISA | BP0301 | IP0070 | |
| SIM0018-1MG | InVivoSIM anti-human integrin α4β1 (VLA-4) | Natalizumab | Human IgG4, κ | Functional assays , Flow cytometry | BE0092 | IP0070 | |
| SIM0019-1MG | InVivoSIM anti-human HER2 (Pertuzumab Biosimilar) | Pertuzumab | Human IgG1, κ | Functional assays, ELISA, Neutralization | CP174 | IP0070 | |
| SIM0020-1MG | InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar) | Ustekinumab | IgG1, κ | Functional assays, | CP174 | IP0070 | |
| SIM0021-1MG | InVivoSIM anti-human PD-L1 (Avelumab Biosimilar) | Avelumab | IgG1, λ | Functional assays, ELISA, in vitro PD-L1 blockade | CP169 | IP0070 | |
| SIM0022-1MG | InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) | Anifrolumab | IgG1, κ | Functional assays, Western blot, ELISA | CP175 | IP0070 | |
| SIM0023-1MG | InVivoSIM anti-human IL-4Rα (CD124) (Dupilumab Biosimilar) | Dupilumab | IgG4, κ | Functional assays, | CP147 | IP0070 | |
| SIM0024-1MG | InVivoSIM anti-human integrin α4β7 (LPAM-1) (Vedolizumab Biosimilar) | Vedolizumab | IgG1, κ | Functional assays, ELISA, Western blot, | CP149 | IP0070 | |
| SIM0025-1MG | InVivoSIM anti-human IL-23 (p19) (Guselkumab Biosimilar) | Guselkumab | IgG1, λ | IL-23p19 neutralization, Functional assays, ELISA, Western blot, | CP169 | IP0070 | |
| SIM0026-1MG | InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar) | Zolbetuximab | IgG1, κ | Functional assays, , | CP174 | IP0070 | |
| SIM0027-1MG | InVivoSIM anti-human PD-L1 (Durvalumab Biosimilar) | Durvalumab | IgG1, κ | ELISA, Flow Cytometry, Western Blot, Functional assays | CP149 | IP0070 | |
| SIM0028-1MG | InVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar) | Denosumab | IgG1, κ | Functional assays, Flow Cytometry, | CP174 | IP0070 | |
| SIM0029-1MG | InVivoSIM anti-human IL-17A (Ixekizumab Biosimilar) | Ixekizumab | IgG4, κ | Functional assays, ELISA, Immunofluorescence, Flow Cytometry, Western blot | CP147 | IP0070 | |
| SIM0030-1MG | InVivoSIM anti-human IL-6 (Siltuximab Biosimilar) | Siltuximab | IgG1, κ | Functional assays, ELISA, | CP174 | IP0070 | |
| SIM0031-1MG | InVivoSIM anti-human nectin-4 (Enfortumab Biosimilar) | Enfortumab | IgG1, κ | Functional assays, ELISA, Western blot | CP174 | IP0070 | |
| New (1/3/2024) | SIM0032-1MG | InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) | Lecanemab | IgG1, κ | Functional assays | CP174 | IP0070 |